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Abstract 
 
Arsenic (As) is one of the oldest poisons known to men. Its applications throughout history 
are wide and varied: murder, make-up, paint and even as a pesticide. Chronic As toxicity is a 
global environmental health problem affecting millions of people in the Unites States and 
Germany to Bangladesh and Taiwan. Worldwide, As is released into the environment by 
melting of various metals, combustion of fossil fuels, as herbicides and fungicides in 
agricultural products. The drinking water in many countries, which is tapped from natural 
geological resources, is also contaminated as a result of the high level of arsenic in 
groundwater. The environmental fate of As is contamination of surface and groundwater with 
a contaminant level higher than 10 particles per billion (ppb) as set by World Health 
Organization (WHO). Arsenic exists in both organic and inorganic species and either form 
can also exist in a trivalent or pentavalent oxidation state. Long-term health effects of 
exposure to these As metabolites are severe and highly variable: skin and lung cancer, 
neurological effects, hypertension and cardiovascular diseases. Neurological effects of As 
may develop within a few hours after ingestion but usually is seen in 2-8 weeks after 
exposure. It is usually a symmetrical sensori-motor neuropathy, often resembling the 
Guillain-Barré syndrome. The predominant clinical features of neuropathy are paresthesias, 
numbness and pain, particularly in the soles of the feet. Electrophysiological studies 
performed on patients with As neuropathy have revealed a reduced nerve conducting velocity 
(NCV), typical of those seen in axonal degeneration. Most of the adverse effects of As are 
caused by inactivated enzymes in the cellular energy pathway, whereby As reacts with the 
thiol groups of proteins and enzymes and inhibits their catalytic activity. Furthermore, As-
induced neurotoxicity, like many other neurodegenerative diseases, causes changes in 
cytoskeletal protein composition and hyperphosphorylation. These changes may lead to 
disorganization of the cytoskeletal framework, which is a potential mechanism of As-induced 
neurotoxicity.  
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Introduction 
 
The word arsenic is derived from the Persian zarnikh: رزHIJ , meaning ‘yellow orpiment’.1 In 
Aramaic (ךינרז) and Arabic (HIذرSTأ), the word was borrowed from the Persian.  It came to the 
Western languages through the Greek rendering of zarnikh: ’αρσενικόν: arsenikon, which, in 
Greek, also means ‘masculine’. Arsenic sulphide also occurs in a red form: realgar or 
sandarach. Long known and used in Persia and elsewhere since ancient times, As was also 
used in traditional Chinese and Indian medicine and as a cosmetic product in eye shadow in 
the Roman era. Given that the symptoms of acute As poisoning are easily confused with acute 
diarrhea associated with cholera, it quickly became a favorite homicidal agent. In 1832, a 
certain John Bodle was brought to trial for poisoning his grandfather by putting As in his 
coffee. James Marsh, a chemist working at the Royal Arsenal in Woolwich was called by the 
prosecution to detect its presence.2 He performed the standard test by passing hydrogen 
sulfide through the suspect fluid. While Marsh was able to detect As, the yellow precipitate 
did not keep very well, and by the time it was presented to the jury it deteriorated. The jury 
was not convinced, and John Bodle was acquitted. Angered and frustrated by this, especially 
when John Bodle confessed later that he had indeed killed his grandfather, Marsh decided to 
devise a better test to demonstrate the presence of As. Taking Scheele's method as basis, he 
constructed a simple glass apparatus capable of not only detecting minute traces of As but 
also of measuring its quantity. While the Scheele test used nitric acid, in Marsh's case the 
suspect fluid would be mixed with sulfuric acid (H2SO4) and passed through a U-shaped tube 
with a piece of arsenic-free zinc at the end (Fig 1). Even a slight trace of As would cause 
arsine gas to form. When he ignited this gas, it decomposed into As and hydrogen and when 
he held a cold ceramic bowl against the flame, the As formed a silvery-black deposit mirror 
on the bowl. Not only could minute amounts of As be detected (as little as 0.02 mg), the test 
was very specific for As. Although antimony (Sb) could give a false-positive test by forming 
a similar black deposit, it would not react with sodium hypochlorite (NaOCl), while As 
would.2,3 
 
 
Fig 1. Schematic representation of the Marsh apparatus. (A) hydrogen generator, (B) chloride of calcium drying 
tube, (C) hard glass-tube and (D) Arsenic mirror. 
 
Due to its use by the ruling class for killing one another and the incredible potency and 
discreetness, As has been called the Poison of Kings and the King of Poisons. The idea of 
using As as a murder weapon can even be seen in early movies and theater shows such as 
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Frank Capra’s ‘Arsenic and old lace’, in which two elderly ladies used As in wine to kill their 
male suitors. 
Arsenic has a long history of use as an intentional poison. Perhaps the most famous victim of 
As poisoning was Napoleon Bonaparte. He seems to have been exposed chronically during 
1816, as appeared from neutron activation analysis of a hair sample.4 A much lower 
concentration was found, however, in another hair sample attributed to Napoleon,5 which may 
indicate that the identity of at least one of these samples should be questioned. One of the 
most prolific As poisoners in history was Goeie Mie ('Good Mary') of Leiden, The 
Netherlands, who lived in the 19th century. She poisoned at least 102 friends and relatives 
between 1867 and 1884, distributing arsenic-trioxide in hot milk to her victims after opening 
life insurance policies in their names. Of the 102 people poisoned, 45 persons became 
seriously ill, often with neurological symptoms, and 27 persons died; 16 of whom were her 
own relatives.6  
Arsenic is used in folk medicine and in pesticides in many countries and also in modern 
western medicine for the treatment of leukemia.7,8 In traditional Chinese medicine, 
preparations can be obtained in the form of coated or uncoated pills, powder or syrups. 
Different studies have shown that the majority of traditional Chinese medicines, such as 
Chinese herbal balls, show high doses of As varying between 0.1 and 36.6 mg per tablet, 
causing patients to get intoxicated by the high As dose, and Indian ayurvedic herbal medicine 
products are also known to cause lead, mercury and As intoxication.9-12 Nowadays, the 
therapeutic use of As is making a comeback in modern medicine. Arsenic trioxide (ATO), for 
instance, is used to treat patients with relapsed acute promyelocytic leukemia (APL).13-16 But 
ATO is also known for its less favorable side, as in causing temporary cardiac and neurotoxic 
side effects in APL patients.8 Arsenic was one of the primary ingredients in pesticides before 
synthetic organic pesticides were available; its long-term application in agricultural pesticides 
has resulted in high levels of arsenic in the body of workers, who are exposed by inhalation 
during the spraying. Arsenic-containing rodent pesticides used for pest and insect control 
were banned due to human health concerns in production, use, and accidental poisoning and 
possible abuse in intentional poisoning. Various case reports and studies have revealed that 
exposure to As has resulted in various forms of cancer and peripheral neuropathy.7,17,18  
 
Acute and chronic exposure to arsenic  
 
Acute. A single exposure, to a high dose may lead to severe reactions such as diarrhea, 
vomiting, pain, dehydration and weakness. Nowadays, acute intoxication rarely occurs in 
western European countries; if it occurs, it is usually the result of intentional (suicide or 
homicide) or accidental poisoning. Occupational exposure to As is rare and usually occurs in 
the form of arsine gas, which causes symptoms different to those caused by As ingestion.6 
Exposure often occurs when arsine gas escapes during transport or when it is generated while 
arsenic-containing ores or metals are treated with acid.19,20 Acute oral exposure to As is 
associated with gastrointestinal symptoms such as nausea, vomiting, abdominal pain and 
severe diarrhea. Cardiovascular and respiratory symptoms include hypotension, shock, 
pulmonary edema and heart failure. If survived, acute poisoning with As is also combined 
with neurological symptoms like light-headedness, weakness, delirium, encephalopathy and 
peripheral neuropathy, which have been reported.21 Peripheral neuropathy as a result of As 
intoxication may be delayed several weeks after the initial toxic insult.22 After a few weeks 
the patients show signs of recovery, however, when tested with electrophysiological studies 6 
to 8 years after exposure, the patients still showed reduced motor conduction velocity.22 
Biopsies on the sural nerves 10 weeks after exposure showed axonal degeneration, which was 
at an early stage in some fibers. These findings suggest that diminished nerve velocity 
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conduction is a severe and latent effect of As intoxication, which contributes to As-induced 
neuropathy. 
Chronic. Environmental and occupational As exposure is not only caused by contaminated 
drinking water due to the leaching of natural geological resources, but may also occur from 
mining and other industrial processes.23 
Chronic ingestion of low concentration of As levels can occur through industrial accidents, 
work and environment, which eventually may cause a higher tolerance for As. An example of 
such an industrial accident can be found in the early 20th century, in reports on As intoxication 
caused by contaminated beer in Salford, UK.24 The subject of these reports, the patients, had a 
few symptoms in common, they all suffered from ‘peripheral neuritis’ characterized by 
weakness in the limbs that made it difficult for them to walk25. In several cases some of the 
patients suffered from rashes and itching, sometimes these complaints were accompanied by 
darkening of skin texture. The presence of As in the beer was due to the use of contaminated 
glucose and inverted sugar by the brewers. Furthermore, the contamination of this sugar is 
caused by the use of very impure sulphuric acid. The source of As contamination was traced 
back to invert sugar, which was caused by the action of sulphuric acid on various forms of 
starch. The original source was the Spanish pyrites from which the sulphuric acid was made 
and often contained large percentages of As. 
Chronic As poisoning represents a global, serious health concern, if As can be found in high 
concentrated levels in the environment from natural or industrial processes. Arsenic 
contamination of groundwater has occurred in various parts of the world such as in the 
Americas, Bangladesh, India, Taiwan and many other Asian countries. In Bangladesh, a 
country of 125 million, between 35-77 million people are currently exposed to As through 
drinking water, which is also the major cause of death, especially among children.26,27 As a 
quick and inexpensive solution for the lack of sufficient and clean drinking water, UNICEF 
and the World Bank advocated to tap into deeper groundwater. Millions of wells were 
constructed; infant mortality and gastrointestinal illness were reduced by half. However, later 
studies revealed that over 40% of these wells are contaminated with arsenic. As a result, due 
to the daily exposure to As in their drinking water, the population in south east Asia has to 
endure various ailments caused by As. Chronic symptoms of As exposure are pigmentation 
changes, gastrointestinal symptoms, anemia, liver disease, a metallic taste and Mees’ lines on 
the nails,28 blackfoot disease and diabetes mellitus.29 Apart from pigmentation changes, 
arsenic-induced skin pathology caused by chronic intoxication also causes hyperkeratosis, 
Bowen’s disease, squamous cell carcinoma and basal cell carcinomas.30,31 Hafemann et al. 
(2005) have shown an association between arsenic exposure and peripheral neuropathy in the 
Bangladesh population that has been chronically exposed to arsenic in drinking water. They 
showed that increased As exposure, as measured by both cumulative and urinary measures, 
was associated with evidence of sub-clinical sensory neuropathy. The correlation between As 
exposure and neuropathy was shown with the increased vibrotactile threshold, a sign of 
subclinical sensory neuropathy, on the one hand and sub-clinical loss of vibratory sensation in 
the lower extremities, on the other hand.32  
 
Diagnosis and treatment of As poisoning 
 
Arsenic concentration measurements for diagnostic purpose are usually carried out in urine. 
Acute As toxicity is usually diagnosed by increased urinary As in excess of 50 µg/l urine 
sample or 100 µg in 24-hour urine, and a shorter time span before examination, if no seafood 
has been ingested. The urine is collected in metal-free containers. Other biological samples, 
such as blood, and even hair and nails in chronic cases, are also used in the clinical laboratory. 
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For treatment of acute As poisoning, the primary concern is to correct the dehydration caused 
by As and restore vital bodily functions. In order to increase elimination, physicians prescribe 
gastric lavage and activated charcoal, but haemodialysis may also be considered. The efficacy 
of these detoxification methods, however, has not been well recorded. Although the metalloid 
As cannot be categorized as a metal, it shows some metal properties. Based on this fact, 
chelators can be used to remove As ions from the body. For treatment of acute As poisoning, 
the chelator 2.3-dimercapto-1-propanol (British Anti-lewisite, BAL) has been used with 
successful results.33,34 Patients who were administered this drug showed elevated As excretion 
in their urine. At follow-up, their urinary As concentration was decreased to the background 
level. At the moment of admittance, neurological examination demonstrated no signs of 
nervous system depression. However, these patients survived the high dose of ingested As 
with only latent neuropathy symptoms. Neurological complications such as distal, 
symmetrical, sensory, axonal neuropathy are late effects of acute As poisoning. These 
neurological effects are non-responsive to chelation.35 In clinical cases with chronically 
poisoned patients, trials with 4 As chelators such as BAL, meso-2.3-dimercaptosuccinic acid 
(DMSA), D-penicillamine and sodium 2.3-dimercapto-1-propamesulfonate (DMPS) did not 
provide any clinical, biochemical or histopathological benefits.36,37 On the other hand studies 
done in rats with an As chelator such as BAL showed depletion of tissue As and its excretion 
via urine and faeces.38  Although the binding affinity of a chelating agent for the metal is 
greater than for endogenous ligands, chelating is generally ineffective for treating established 
arsenical peripheral neuropathy.39 
 
Kinetics of various arsenic metabolites and their molecular mechanism of toxicity 
 
Kinetics. Arsenic absorption takes place mainly in the small intestines; also a minimal 
absorption occurs from skin contact and inhalation.31,40,41 After ingestion, As is metabolized 
from inorganic to organic compounds with varying degrees of toxicity and the behavior of the 
different As species vary markedly. Arsenic speciation of inorganic and organic forms of As 
is often as important as total quantification, because of their different toxicity and mobility.42 
As speciation in biological samples is an essential tool to gain insight into its distribution in 
tissues and its specific toxicity to target organs. 
Arsenic metabolites exist both in organic and inorganic forms and both types can exist in 
either trivalent or pentavalent oxidation states. The bioavailability of inorganic As is up to 
60%. Inorganic As such as arsenate (iAsV), the pentavalent form, and arsenite (iAsIII), the 
trivalent form, are the most aggressive single-substance toxicants, specially the trivalent form. 
A redox reaction reduces the pentavalent As to its trivalent state. This reduction step from 
pentavalent to trivalent, releases a more toxic compound, which in fact results in bio-
activation (Fig. 2).  
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Fig. 2. Two possible pathways are shown for arsenate methylation. The main pathway is a straightforward bio-
activation (metabolic activation) of arsenate in MMA, DMA and the theoretical conversion into TMA (not 
shown).46,53,59 A possible second pathway is direct metabolism of iAs (A) to either MMA without further 
conversion to DMA or (B) increase in DMA levels, while the MMA levels stay intact.44 
 
Arsenic metabolism shows a common route of absorption, distribution and excretion both in 
humans and various animals with subtle interspecies differences. Metabolism of inorganic As 
starts with intake and absorption. Distribution of As varies per species. This is a result of 
various factors such as species, bodyweight, route of intake and duration of exposure. After 
its absorption, As can be found in different organs, especially in the liver.43,44 Arsenic 
undergoes hepatic biomethylation to form monomethyl arsenic (MMA) and dimethyl arsenic 
(DMA). Various in vitro studies on human and animal livers reveal the next step in iAs 
detoxification (Fig. 2). Detoxification starts with transformation of inorganic As to organic As 
and reduction of pentavalent arsenate to trivalent arsenite, which results in a more toxic 
component. The reduction of arsenate to arsenite is catalyzed by gluthatione (GSH) and other 
thiols, which are reducing agents.45 Arsenate at physiological pH is ionized and as such is not 
able to pass cellular membranes. Conversion to arsenite at physiological pH facilitates 
passage through the cellular membrane.  
Metabolism of As continues by using arsenite as its substrate for methylation, which is 
distributed in tissues and cytosol. However, methylation does not appear to be the primary 
detoxification pathway for arsenite. Protein binding has been suggested as the initial 
protective mechanism. Arsenite binding to protein serves as a reservoir and takes place after 
initial increase in arsenite concentration. When methylation enzymes start to become 
effective, the reservoir may slowly release small amounts of arsenite for methylation.46 The 
methylation of arsenite is catalyzed by a specific methyltransferase using s-
adenosylmethionine as a methyl donating cofactor (SAM).43,47 Addition of a methyl group to 
arsenite leads to synthesis of pentavalent monomethylarsonic (MMAV). The MMAV in turn is 
reduced to trivalent MMA (MMAIII) by GSH, the reducing agent. Another round of 
methyltransferase activity with MMAIII results in production of dimethylarsenic acid (DMA). 
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However, it is not clear whether the same SAM is used for methylation of MMA and DMA or 
that two separate SAMs are being used for these two methylation steps. Theoretically, 
conversion of arsenate to DMA could be extended by one more round to achieve 
trimethylarsenic acid (TMA).43,48 A second possible conversion route to MMA and DMA was 
introduced by the in vitro studies of Buchet and Lauwerys, by adding mercuric ions; they 
prevented the formation of DMA without affecting MMA formation.44, 45 Furthermore, it was 
evident that the addition of cyanocobalamin or methylcyanocobalamin (vitamin B12) and 
coenzyme B12 in combination with SAM resulted in a significant increase of DMA and no 
additional increase in MMA level. This experiment revealed two different enzymatic 
activities involved in methytransferase to either MMA or DMA (Fig 2). 
The methylation process has been thought to be the detoxification mechanism for As. This is 
true when this line of reasoning is applied to parameters of acute toxicity of As species, such 
as LC50 or LD50. As a rule, the trivalent As compounds are more cytotoxic then their 
pentavalent forms. However, various studies in animals and cell cultures have shown the 
adverse effects of methylated As, such as DMAV as a tumor promoter49,50 or direct genotoxic 
action of MMAIII and DMAIII in vitro.43,51 
The main excretion route of As is through the urine and bile. However, the various As 
metabolites do not excrete in the same fashion in different animals and humans. For example, 
studies in rats have shown that pentavalent metabolites such as iAsV, MMAV and DMAV are 
exclusively excreted into urine, MMAIII only into bile and iAsIII into both bile and urine.52  In 
contrast, human studies revealed the presence of MMAIII in urine.53,54 Arsenic studies carried 
out by Csanaky and Gregus in rats, mice, hamsters, rabbits and guinea pigs revealed some 
similarities. All species injected with iAsV excreted various As metabolites into urine, in 
contrast to injection with iAsIII, which showed higher excretion into bile rather than urine.52 
Mechanism. These metabolites exert their toxicity by inactivating many enzymes, especially 
those involved in the cellular energy pathway and DNA synthesis and repair. Arsenic is 
substituted for phosphate in high-energy compounds such as ATP. Arsenic binds covalently 
with sulfhydryl groups in their reduced form. These interactions also take place with certain 
enzymes necessary for cellular metabolism.17 Various As carcinogenesis studies have 
revealed that As may alter one or more DNA repair processes. Andrew et al. have shown that 
patients exposed to As have altered nucleotide excision repair mainly on the excision repair 
cross-complementing 1 (ERCC1) component. Arsenic exposure was associated with 
decreased expression of ERCC1 in isolated lymphocytes at the mRNA and protein levels.55 In 
short, As exposure results not only in general toxicity but also in neuronal diseases and 
carcinogenesis.  
Tri-valent arsenic (iAsIII, MMAIII and DMAIII) compounds are thought to interact with thiol 
groups of proteins and enzymes in their reduced state. This is believed to inhibit the catalytic 
activity of enzymes.54 The common thinking is that tri-valent arsenic metabolites inhibit 
pyruvate dehydrogenase (PDH), which leads to disruption of the energy system of the cell,56 
which in turn may release an apoptosis-inducing factor (AIF) resulting in cell damage and 
death. AIF is released from the mitochondrial intermembrane space from where it translocates 
to the cell nucleus.57 Apoptosis is associated with early formation of ring-like perinuclear 
condensed chromatin co-localized with AIF, DNA fragmentation and finally cell death. 
Pentavalent As (iAsV, MMAV and DMAV) is substituted for phosphorus in many biochemical 
reactions. Replacing the stable phosphorus anion in phosphate with the less stable AsV anion 
leads to rapid hydrolysis of high-energy bonds in compounds such as ATP. At the level of the 
citric acid cycle, As inhibits succinate dehydrogenase and by competing with phosphate it 
uncouples oxidative phosphorylation, thus inhibiting energy-linked reduction of NAD+, 
mitochondrial respiration, and ATP synthesis. This leads to loss of high-energy phosphate 
bonds and effectively uncouples oxidative phosphorylation.58,59 
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Another approach is that trivalent As inhibits enzyme complexes by reactive oxygen species 
(ROS), indicating that ROS production by trivalent As causes pyruvate dehydrogenase (PDH) 
inactivation through oxidation.60 Inactivation through oxidation causes impaired 
gluconeogenesis and reduced oxidative phosphorylation.61 Production of ROS by As was 
determined by use of a nonfluorescent dye 5’,6’-chlomethyl-2’,7’-dichlorodihydrofluorscein 
(CM-H2DCFDA), which is a non-specific radical detector to identify the radical species.
62 
Cells pretreated with CM-H2DCFDA and subsequently exposed to arsenite exhibit a dose-
dependent increase in fluorescence levels within minutes of treatment when compared to 
controls.63  Using DMSO in these experiments as radical scavenger in the reaction mix 
reduced the fluorescence signal to a near-background level. 
 
Arsenic-induced neurotoxicity 
 
Arsenic effects manifest themselves weeks after first exposure as both central and peripheral 
neuropathy. Central neuropathy due to As poisoning has been reported to cause impairment to 
neurological functions such as learning, short-term memory and concentration.64 People 
chronically poisoned by arsenic occurring naturally in groundwater may suffer from toxic 
delirium and encephalopathy.39 Neuropsychological tests showed mildly impaired 
psychomotor speed and attentive processes, whereas verbal learning and memory were 
severely impaired.  
The most frequent neurological manifestation by As is peripheral neuropathy that may last for 
several years or even life-long. The peripheral neuropathy may lead to rapid severe ascending 
weakness, similar to the Guillan-Barré syndrome, requiring mechanical ventilation. Peripheral 
neuropathy is common in persons chronically exposed to As-contaminated drinking water.65 
From human clinical cases studied by Le Quesne and McLeod it has become clear that As 
exposure results in a latent reaction to the nervous system, which was established through 
their reduced Nerve Conduction Velocities (NCVs)  measurements.22 These patients showed 
some recovery in the years following exposure to As; however, a full NCV regain was not 
achieved. It is doubtful whether PNS symptoms will ever disappear completely. 
Patients exposed to As show significantly lower NCVs in their peripheral nerves in 
comparison to their referents.21,34,66 Perhaps, changes in cytoskeletal composition may be the 
major reason of As poisoning leading to axonal degeneration, which in turn could lead to 
axonopathy. 
An actual mechanistic model for arsenic neurotoxicity is as yet not easy to hypothesize, 
although interference with cytoskeletal proteins is a primary consideration.  Therefore, one 
may look for such mechanistic parallels in other neurotoxins, especially neurotoxic metals, 
but also in other neurodegenerative diseases.  
Metals as environmental pollutants such as lead and mercury have been associated with 
neurodegenerative diseases.67 Exposure to aluminum, lead and mercury are known to have 
caused abnormalities in the nervous system related to interference with the cytoskeleton. 
Clinically, symptoms may occur as peripheral and central neuropathies. Aluminum has been 
known to cause dialysis encephalopathy in some individuals with renal failure. Furthermore, 
it has been suggested that aluminum might be implicated in Alzheimer’s disease (AD), 
because of some similarities in pathological changes. The pathological changes in both cases 
can be summarized as presence of neurofibrillary tangles as diagnostic hallmarks AD.68 
However, further examination of these tangles has shown differences in their tangles between 
AD and the aluminum-exposed patients, in AD patients tangles consist of paired helical 
filaments, whereas those induced by aluminum are single.69  Aluminum exposure in animal 
studies has shown induction of neurofibrillary degeneration. Phosphorylation of cytoskeletal 
proteins appears to modulate their interactions with one another and with other cellular 
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proteins. Disruption of the phosphorylation of cytoskeletal proteins results in disorganization 
of the cytoskeletal structure.70 Other metals as neurotoxicants such as lead have also been 
indicated in the etiology of amyotrophic lateral sclerosis (ALS), whereas manganese has been 
reported to be involved in Parkinson’s disease (PD) or a similar syndrome, Parkinsonism. 
Exposure to lead has been shown to be related to ALS in a case control study conducted in 
New England from 1993 to 1996.71,72 Generally, ALS is divided into two forms: (1) the 
classic sporadic form; (2) the familial, presumably hereditary form. The cause of the sporadic 
form is unknown. The cause of the familial form is believed to be genetic, attributable to a 
mutation in Cu–Zn superoxide dismutase.73 Studies in occupational exposure have suggested 
an association between PD and elevated exposure to manganese.74 Exposure to manganese 
can cause neurotoxicity and a neurological syndrome that resembles PD.75 
Neurofilament proteins are major constitutes of neurons and they control axonal caliber, 
transport and signal.76 In neurodegenerative diseases such as AD it appears that the 
metabolism of neurofilaments is disturbed, as indicated by the presence of neurofilament 
epitopes in the neurofibrillary tangles, as well as by the severe reduction of the expression of 
the gene for the light neurofilament subunit of the neurofilament triplet (neurofilament High, -
Middle and –Light) in brains of AD patients.77 Accumulation of neurofilaments in the 
proximal cell body and the perikaryon of motor neurons is a hallmark of ALS and PD.73,76 
Disruption and disorganization of neurofilament transport and neuron cytoskeletal network is 
a pathological feature seen in all of these neurodegenerative diseases.  
In rats exposed to As , decrease of the neurofilament Light subunit (NF-L) in sciatic nerve is 
evident.78 Arsenic-induced decrease of NF-L may play an important role in the pathological 
changes of the nervous system, since NF-L is the only NF protein capable of independently 
organizing and co-assembling filaments in vivo. Both NF-H and NF-M need NF-L protein to 
form a heteropolymer in the cytoskeletal framework.79 However, in vitro studies with iAsIII in 
neuroblastoma (SK-N-SH) and Schwannoma (ST-8814) cell lines show no effect on their 
mRNA expression level of cytoskeletal genes.80 Thus, it can be suggested that the decrease in 
NF-L expression is a post-translational activity as a result of a proteolytic process. Calpain 
(calcium-activated cytoplasmic protease) could be responsible for NF-L degradation, since 
neuroblastoma cells (SY-5Y) treated with arsenic trioxide (trivalent As) show an increase in 
intracellular calcium.81 Studies in PC12 cells under oxidative stress circumstances have 
shown an increase of calcium in the cells and up-regulation of calpain leading to degradation 
of NF-L protein.82 Furthermore, inactivation of calpain by calpain inhibitor (MDL-28170) 
prevents NF-L breakdown.83,84 These results suggest that As-induced destabilization and 
disruption of the cytoskeletal framework is partly due to activation of calpain, through influx 
of Ca2+, which in turn is responsible for NF-L degradation in a calcium-induced proteolytic 
process. 
Another important cytoskeletal protein in neurodegenerative diseases is the tau protein (MAP-
tau), which is a member of the microtubule protein family transcripted by alternative splicing 
of a single gene. It has tandem repeats of a tubulin binding domain and promotes tubulin 
assembly. Although tau proteins are found in all cells, they are major components of neurons 
where they are predominantly associated with microtubules of the axon. Changes in tau-
protein may play a role in the pathogenesis of neurodegenerative diseases. In AD patients, 
MAP-tau becomes abnormally hyperphosphorylated and accumulates as tangles of paired 
helical filaments in neurons undergoing degeneration. Hyperphosphorylated MAP-tau 
disorganizes microtubules assembly from normal tau and tubulin, which may lead to the 
formation of the neurofibrillary tangles and the degeneration of the affected neurons in AD 
patients. Arsenic may affect the phosphorylation of tau-proteins as well. Giasson et al. 
demonstrated hyperphosphorylation of tau-proteins in Chinese hamster ovary (CHO) cells in 
vitro after treatment with iAsIII.85 They also showed that iAsIII causes a significant increase in 
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the phosphorylation of several amino acid residues in tau. This is in line with experiments in 
rats with iAsIII, which have also shown that the rats’ MAP-tau was hyperphosphorylated after 
dosing them with iAsIII {unpublished data}. These results indicate that As may be involved in 
the cascade leading to deregulation of tau function associated with neurodegeneration. 
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Conclusion 
 
Arsenic compounds are toxic substances with very profound effects on human health. 
Metabolism of As involves reduction of pentavalent As to a trivalent state and subsequent 
oxidative methylation. The adverse effects caused by As metabolites vary. The molecular 
mechanism of action can be summarized as involvement in cellular energy pathway, 
disruption of oxidative phosphorylation, hyperphosphorylation and altering the DNA 
synthesis and repair. Acute As intoxication has only been treated successfully with BAL. 
Furthermore, none of the chelators have ever been successful in treating chronic As 
intoxication. Arsenic neuropathy occurs weeks or even months after initial exposure in the 
acute cases, and it is also present in chronically exposed patients. Reduced nerve conducting 
velocity in PNS is a hallmark of As neuropathy. The neuropathy is primarily due to 
destruction of axonal cylinders and compositional changes, leading to axonopathy. The 
cytoskeletal changes are caused by disruption of the neurofilament and microtubule network 
in the nerve cells, namely through gradual degradation of NF-L by calpain, since iAsIII does 
not affect expression on gene level and hyperphosphorylation of NF-L and MAP-tau. The 
probable functional disturbances of these proteins such as transport and signaling and 
pathological changes such as reduction in caliber of axons may lead to axonopathy. These 
functional and pathological changes manifest themselves in clinical signs of neuropathy. 
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Aims and objectives of the present investigation 
 
 
Ali Vahidnia 
 
 
 
The aim of this study is to investigate the mechanism by which arsenic (As) induces its 
neurotoxic effects. 
 
Background 
 
The term ‘neurotoxic’ is used to describe a substance, condition or state that damages the 
nervous system and/or brain, usually by killing neurons. The term is generally used to 
describe a condition or substance that has been shown to result in observable physical 
damage.  
Arsenic is a semi-metalloid and exposure to As is a world wide health problem causing 
various disorders and diseases in millions of people around the world. Arsenic causes various 
diseases such as numerous organ cancers and also patients show severe effects on their 
nervous system. The effects on the nervous system may be assessed with the use of clinical 
studies like nerve conduction velocities (NCV). In As exposed patients, their NCVs are 
diminished in comparison to healthy unexposed subjects. However, the mechanisms of As 
neurotoxicity remain somewhat obscure while the instance of As exposure, especially at 
chronic levels, remains a prevalent human health concern.   
To start our investigation we had to ask the pertinent questions that comes with any 
investigations; why? How? And what kind of strategies must be taken? 
 
Objectives and investigation of this thesis 
 
As the molecular mechanism of arsenic neurotoxicity has not been described before, it was 
our aim to elucidate this mechanism.  To start this investigation, we had to see whether the As 
effect that can be measured by reduced NCV, can be shown on molecular level in nerves. We 
devised studies in rats (in vivo) to determine the possible effects of As on the nervous system 
(Chapter 3 & 4). These studies were designed to answer whether As effects could be found on 
the nervous system and whether these effects could be established by different rout of 
exposure, dose and duration. 
We studied the acute short effects of high As doses intravenously after a single exposure 
(Chapter 3) and the subchronic effects of intragastric administration of As for a longer 
exposure (Chapter 4). These studies deal with the effects of inorganic As in Wistar rats on the 
cytoskeletal protein composition of the sciatic nerve after acute and subchronic intoxication. 
The strategy in these two studies were to chart the pharmacokinetics in blood and urine and 
concentration in sciatic nerve and correlated them with effects that could arise on PNS with 
help of western blot technique on various cytoskeletal proteins.  
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After establishing the As effect in vivo, we started further investigation on the possible 
mechanisms of As neurotoxicity in vitro. In vitro studies were designed to study various As 
metabolites and compare their effects on genetic level for various cell cultures derived from 
neuroblastoma (SK-N-SH) or Schwannoma (ST-8814) representatives for nervous system, as 
well as non-neuronal derived cells such as, HeLA and Chinese Hamster Ovaries (CHO). 
These cell lines were chosen as a model for neurons as they harbor the mentioned neuro-
cytoskeletal proteins like NFs and MAP-tau. We examined the (neuro-) toxic effects of 
various arsenic metabolites on these cells. The DNA expression levels of cytoskeletal proteins 
and genes involved in phosphorylation were studied after exposure to various arsenic 
metabolites and concentrations. The effects were examined on the relative quantification 
levels of the cytoskeletal genes, using Real-Time PCR (Chapter 5 & 6). To conclude these 
studies, the mechanism of NFs and MAP-tau phosphorylation was studied with the use of a 
p35 construct in HeLa cell line (Chapter 6). CHO cell lines such as AA8, UV20 and UV5 
were also used to get additional information, especially to investigate effects of various As 
metabolites on the DNA repair mechanism namely nucleotide excision repair genes such as 
Ercc1 and Ercc2 (Chapter 7). 
 
 
  
Chapter 3: Arsenic neurotoxicity I 
 
Arsenic-Induced Toxicity: Effect on Protein Composition 
in Sciatic Nerve  
 
 
 
 
 
 
 
 
 
 
Chapter 3 
 30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arsenic Neurotoxicity I 
 31  
Arsenic-Induced Toxicity: Effect on Protein Composition 
in Sciatic Nerve 
 
 
A Vahidnia*
,1
, F Romijn
2
, M Tiller1, GB van der Voet1, FA de Wolff1 
 
Department of Clinical Pharmacy and Toxicology1 and Department of Clinical Chemistry2, 
Leiden University Medical Center, Leiden, the Netherlands 
 
 
Abstract 
 
Exposure to arsenic (As) compounds may lead to skin and lung cancer and various disorders 
such as vascular disease and peripheral neuropathy in humans. Peripheral arsenic 
neurotoxicity has been demonstrated clinically and in electrophysiological studies. Patients 
intoxicated with arsenic show neurological symptoms in their feet and hands. These patients 
show significantly lower nerve conduction velocities (NCVs) in their peripheral nerves in 
comparison with controls. The mechanism of As PNS toxicity, however, has never been 
described before. This is the first study to investigate the toxicity of As on the peripheral 
nervous system (PNS). Male Wistar rats were exposed to arsenite given as a single dose i.v. 
After sacrifice, sciatic nerves were excised and the protein composition was analyzed. Protein 
analysis of sciatic nerves showed disappearance of neurofilament and fibroblast proteins in 
rats treated with arsenite doses of 15 and 20 mg/kg in comparison with the control groups. 
Some fibroblast protein bands had disappeared in the 20-mg/kg dose group. The analyzed 
neurofilament-M and -L proteins decreased dose-dependent over time. Arsenic affects the 
composition of proteins in the rat sciatic nerve, especially the neurofilaments. The reduction 
of signals in western blot analysis reveals changes in cytoskeletal composition, which may 
well lead to neurotoxic effects in vivo. 
 
Keywords: arsenic, arsenite, fibroblast, neurofilament, neurotoxicity, Nervus ischiadicus
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Introduction 
 
Arsenic is a toxic, natural contaminant in soil, water and air, depending on geography. 
Inorganic arsenic (As) poisoning is a major health issue in large parts of the world, such as in 
India and Bangladesh1 and several South American countries, and is mostly due to 
environmental exposure through water, air pollution2 and soil contamination.  Contaminated 
drinking water in a country such as Bangladesh is an important source of arsenic intake.3 A 
famous example is the arsenical poisoning of drinkers of contaminated beer in England 
toward the end of the 19th century.4-6 Patients showed neurological symptoms in their feet 
and hands, for example, a burning sensation in the soles of the feet and tingling sensations in 
fingers and toes. 
The rat is a species often chosen to study toxicity in order to predict potential effects in 
humans.7 It has been established that rats methylate inorganic arsenic analogous to humans, 
although this process occurs in rats at a faster rate. Although the toxicokinetics of arsenic in 
rats is different to humans, their toxicodynamics are similar.8,9 We, therefore, chose rats as 
our experimental model to investigate neurotoxicity caused by arsenic. It was not the purpose 
of this study to investigate the side effects of therapeutic applications of arsenic. 
Exposure to As by inhalation,10 oral ingestion,5 or injection11 induces neuropathy. Arsenic 
has also been known for its therapeutic properties, as it is used for the treatment of acute 
promyelocytic leukemia (APL). Many APL patients develop symptoms of neuropathy after 
injection with trivalent arsenic as a side effect12 (As2O3) (up to 0.15 µg/kg daily as indicated 
in the manufacturer’s information accompanying the drug Trisenox). It has been suggested 
that trivalent arsenicals inhibit many enzymes by reacting with the sulfur groups present and 
that, as a rule, the trivalent forms of arsenic are the major source of poisoning.13 
A single exposure to arsenic in an acutely toxic dose leads to severe clinical reactions such as 
diarrhea and vomiting, often leading to death through dehydration.14,15 For example, Duenas-
laita et al. described a case of non-fatal acute arsenic poisoning where a very high arsenic 
concentration of 67.5 mg/l was measured in the urine.15 In cases where patients survive, 
recovery occurs weeks after intoxication. However, delayed effects may appear in the form 
of peripheral neurotoxicity both after acute and chronic exposure. These delayed effects of 
arsenic have been demonstrated clinically4,16 and in electrophysiological studies.17 Patients 
show significantly lower nerve conduction velocities (NCVs) in their peripheral nerves in 
comparison to healthy subjects. It is also worth mentioning that in suicidal/accidental cases, 
where a single dose of As was taken, the dose was exceptionally high in comparison to 
chronic exposure or therapeutic dose.15,17,18  
In contrast to the bulk of information on carcinogenicity, the mechanism of As-induced PNS 
toxicity is not yet understood. Our hypothesis is that diminished NCV is probably caused by 
arsenic-induced axonal degeneration, which in turn could change the myelin composition. 
This study presents the first results of a project that are aimed toward elucidating the 
mechanism of the peripheral neurotoxicity of arsenic. As a first step in this investigation, the 
short- and long-term effects of arsenite on rat sciatic nerve proteins were studied as a model 
for peripheral axonopathy. 
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Materials and Methods 
 
Chemicals. Sodium meta-arsenite (NaAsO2 : As
III) (product no. 22,869-9, 98% pure) and 
acrylamide/bis-acrylamide (product no. A 3699, Mix ratio 37.5:1, T30%, C2.6%) were 
purchased from Sigma-Aldrich (St. Louis, Missouri, USA). TEMED (catalog no. 161-0800) 
and sodium dodecyl sulphate (catalog no.161-0301) were purchased from Bio-Rad. Tris-HCl 
(catalog no. 108219) (Veenendaal, Netherlands) and EDTA (catalog no. 108418) were 
purchased from Merck (Darmstadt, Germany). A micro BCA protein assay kit (product no. 
23235) was purchased from Pierce (Rockford, USA). Phosphate buffered saline (PBS, NaCl 
145 mmol/l, phosphate 1.4 mmol/l and pH 7.5) was prepared from analytical grade reagents 
by the Department of Pharmacy. Kodak biomax XAR film (catalog no. 165 1454) was 
purchased from Kodak (Shelton, CT, USA). Coomassie brilliant blue R250 (product no. 
27816) was obtained from Fluka (Buchs SG, Switzerland). ECL plusTM western blotting 
detection reagent was purchased from Amersham Biosciences (Piscataway, NJ, USA). NF-
90 antibody to all three neurofilament proteins (NF-H, NF-M and NF-L) was a gift from 
Prof. E. Marani of the Department of Neurosurgery at the Leiden University Medical Center, 
Netherlands.19 
Animals. Male Wistar rats (225-250g) were obtained from Charles River, Maastricht, 
Netherlands. The rats were acclimatized for 7 days and housed in groups of three in plastic 
cages on sawdust in a 12/12 h light/dark cycle. The rats were fed a standard diet and tap 
water ad libitum in their plastic and metabolic cages. The protocol for this study was agreed 
upon by the Animal Ethical Committee of the Leiden University Medical Center. 
Experimental design. Rats were injected with arsenite dissolved in PBS as a single dose 
(between 0- to 20-mg/kg) in a tail vein. The doses used for short-term single arsenic 
exposure were 0-, 15- and 20-mg/kg AsIII. The long-term single exposures were 0-, 3- and 
10-mg/kg AsIII. The injected volumes varied from 0.30 to 0.35 ml depending on body 
weight.  The control groups were injected with 0.30 ml PBS without any AsIII. Urine samples 
were collected after injection by individual housing of each rat in a metabolic cage. In the 
short-term section of the experiment, rats were kept in metabolic cages for the intended 
duration of 3, 6 and 9 hours. In the long-term section of the experiment, rats were kept in 
metabolic cages 24 hours after injection. Afterwards, rats that received the same dose were 
combined into one group and housed for 2, 3 and 4 weeks in plastic cages on sawdust. After 
the intended duration, rats were individually anesthetized with isoflurane in a plastic sealed 
cage with in- and out-flow tubes. Subsequently, they were exsanguinated by means of 
arterial blood withdrawal from the inferior mesenteric artery after 3, 6 and 9 hours (single-
dose, short-term exposure) or 2, 3 and 4 weeks (single-dose, long-term exposure), 
respectively.  
For the short-term, single-dose exposure, one rat was used for each dose and duration in 
accordance with the guidelines of the Animal Ethical Committee. For the long-term, single-
dose exposure, three rats were used for each dose and duration in accordance with the 
guidelines of the Animal Ethical Committee.  
Nervus ischiadicus arises from the sacral plexus and passes about halfway down the thigh 
where it divides into the common peroneal and tibial nerves. The nerve was dissected on one 
end from the sacral plexus as close as possible to the spinal column and on the other end just 
before its division. The nerve was dissected from both legs and in each case was 
approximately 2 cm in length. In these experiments, the sciatic nerve from the right leg was 
used for protein analysis and the one from the left leg was used for arsenic measurement. 
The blood samples for arsenic analysis were first digested in an acid mixture (digestive acid) 
comprised of one part perchloric acid and one part nitric acid (1:1). Fifty µl of blood sample 
was added to 950 µl of digestive acid and incubated for 1 hr at 70 °C. The sciatic nerve 
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samples were first weighed and digested in 1 ml digestive acid as in blood and incubated for 
1 hr at 70 °C.  The urine samples were first diluted with Milli-Q water (MQ-H2O) with a 
factor of 200 to 250. From the digested blood or nerve or the diluted urine samples 0.5 ml 
was added to 4.5 ml of reduction acid consisting of 216 ml MQ-H2O, 27 ml 37% 
hydrochloric acid (1M HCl), 6 g sodium iodide (NaI) and 3 g L-(+) ascorbic acid (C6H8O6) 
and incubated for 1 hour at 70 °C.  
The arsenic content of urine, digested blood and digested sciatic nerve were measured with 
atomic absorption spectrometry (Perkin-Elmer FIAS-3100 AAS). The technique for 
measuring total arsenic content is hydride generation coupled to AAS (HG-AAS).20 An As 
electrodeless discharge lamp of 7W was used; arsenic absorption was measured at 193.7 nm. 
The matrix of the calibration solution for urine consisted of 4.5 ml 1M HCl and 0.5 ml 
arsenic standard solution dissolved in MQ-H2O ranging from 0.0 µg/l to 200 µg/l end 
concentration. For the digested blood and nerves, the matrix of the calibration solution 
consisted of 4.5 ml 1M HCl, and 0.5 ml of arsenic standard solution dissolved in digestive 
acid ranging from 0.0 µg/l to 200 µg/l end concentration.  
Neurofilament Characterization. Excised sciatic nerves weighing 12.5 mg to 18.5 mg were 
homogenized with a blender in 1.5 ml Tris-HCl buffer (200 mM, pH 8.0), also containing 
EDTA 3 mM and sodium dodecyl sulphate 1% w/v. The nerve homogenates were analyzed 
on a 6% acrylamide separation gel.21 The samples were run non-reduced without the use of 
dithiothreitol (DTT). The protein gels were stained for 3 min with 0.4 g/L Coomassie Blue in 
a fixing solution also containing 40% v/v methanol and 7% acetic acid v/v. Gels were de-
stained in 2 steps with discoloring solution containing 40% methanol and 7% acetic acid. 
Further, the separation gels were also used for immunoblotting on 0.2 µm nitrocellulose 
membrane22 in conjunction with NF-90 monoclonal antibody to all 3 neurofilament proteins: 
NF-H; NF-M and NF-L. Using ECL plusTM western blotting detection reagent and exposing 
the nitrocellulose membranes to Kodak Biomax XAR film for 30 seconds concluded the 
western blot analysis. The band intensities on the Kodak films were measured and compared 
to each other by Quantity One – Densitometer GS-710 from Bio-Rad. 
Fibroblast Characterization. The fibroblast portion of the sciatic nerve was determined by 
separating fibroblasts from Schwann cells by means of magnetic-activated cell separation 
(MACS).23 The sciatic nerve is covered with epineurium consisting of collagen. Inside this 
cover, the nerve harbors nerve cells, Schwann cells and fibroblasts. Excision of the sciatic 
nerve in rats results in the tearing of the motor rootlet; as a result the nerves cannot be 
cultured in vitro. The remaining Schwann cells and fibroblasts can be grown in culture. As 
described previously by Vroemen and Weidner23 the Schwann cells in the 
Schwann/fibroblast culture are incubated with anti-p75LNGFr monoclonal antibodies for 10 
min at room temp.  This antibody is directed at cell surface antigen to select Schwann cells in 
the p75 low affinity nerve growth factor receptor (p75LNGFr). Thereafter, the labeled 
mixture is washed and incubated with secondary antibody, namely: microbead-linked rat 
anti-mouse IgG1 for 15 min at 4˚C. After 2 to 4 wash steps, cells were resuspended in 
MACS buffer (included in the kit) and added to a MS column (also included in the kit) held 
in a magnet, as the secondary antibodies have magnetic properties. Cells were passed 
through the column and washed 4 times with MACS buffer (500 µL). Labeled cells were 
retained in the column, the column was removed from the magnet, and cells were eluted into 
1 ml MACS buffer. The isolation procedure was repeated to increase the purity of the 
isolated cells. At this stage the majority of the fibroblasts are separated from the labeled 
Schwann cells. The content of the fibroblast-eluted portion can be tested next to the 
homogenized sciatic nerve on a separation gel. First the separated fibroblasts are lysed in a 
Tris-HCl buffer, the same buffer that is used in homogenated sciatic nerves. Subsequently, 
the 2 homogenates were loaded on a 6% separation gel and stained with Coomassie Blue.  
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This comparison enabled us to identify the fibroblast protein bands in the whole sciatic nerve 
tissue.  
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Results 
 
General health 
During the single-exposure, long-term effect study, the gain in body weight was used as a 
parameter for general health. Increasing the AsIII dose results in a decrease in body weight 
gain (Figure 1). The difference between weight gain of control rats and the reduced weight 
gain of rats treated with 10 mg/kg AsIII becomes evident after 2 weeks. Furthermore, in the 
dose groups exceeding 10 mg/kg, diarrhea was observed. The 3-mg/kg AsIII doses also 
resulted in diminished appetite and decreased overall alertness levels of the injected rats. The 
body weight in this dose group 2 weeks after exposure increased to such extent that there 
was no significant difference between treated and control animals. 
 
 
 
Figure 1. Body weight gain in control rats and in arsenite-treated rats during 4 weeks. Rats treated with 10-
mg/kg arsenite show significant reduced growth in comparison to the control. The group of 3-mg/kg dosage 
shows recovery in their growth. 
 
Arsenic elimination 
For the long- and short-term single dose effect, the total amount of arsenic excreted in urine 
was measured and expressed as mg As/mmol creatinine (Table 1). The arsenic content in the 
short-term experiment was expressed as excreted total arsenic in the excreted urine volume. 
This is done due to their short survival time of up to 9 hours after injection. The content in 
urine varied from 18.06 to 31.87 mg As/mmol creatinine after 15-mg/kg dose. In the 20-
mg/kg dose group, urinary arsenic varied between 22.56 and 44.13 mg As/mmol creatinine. 
In the long-term exposure group, samples of 24-h urine were collected after injection. In this 
case, the arsenic content in urine varied from 0.34 mg As/mmol creatinine to 2.05 mg 
As/mmol creatinine for the 3-mg/kg dose group. The 10-mg/kg dose group showed arsenic 
concentrations varying between 2.06 to 2.40 mg As/mmol creatinine. 
Table 1 also shows the arsenic content in digested blood (mg/l), which could only be 
measured in the short-term exposure group. The 15-mg/kg group showed arsenic content 
between 1.58 and 2.30 mg/l, while the 20-mg/kg group showed between 2.34 and 2.90 mg/l 
arsenic content in blood. The blood arsenic content of long-term, single exposure rats was 
below the detection limit (As < 5 µg/l).  
The arsenic content in the N. ischiadicus was expressed in µg/l (w/v) and was measured in 
both short- and long-term groups. Digested sciatic nerve was used to study the interaction of 
arsenic with peripheral nerve proteins for various dose groups and duration. In the short-
term, single exposure group, arsenic content of 0.96 to 2.24 µg/g tissue was measured for the 
15-mg/kg dose group and 0.30 to 1.08 µg/g for the 20-mg/kg dose group, both up to 9 hours. 
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The As content in the long-term, single exposure group 3-mg/kg decreased from 0.508 µg 
after 2 weeks to 0.302 µg arsenic per gram tissue after 4 weeks. The sciatic nerve arsenic 
content in the 10 mg/kg dose group also decreased from 0.367 µg arsenic per gram tissue 
after 2 weeks to 0.237 µg arsenic per gram tissue after 4 weeks.  
 
 
Table 1. Total arsenic content in the short-term, long-term, single exposure was measured in 
urine, blood and sciatic nerves.  
   
   Number    Total Arsenic Blood  Nervus 
   of rats     in urine  3 to 9 hrs  ischiadicus 
   per dose    (mg As/  (mg/l)  (µg /g) (ww) 
   group*     mmol creatinine 
 
Short-term 3 Control   0 hrs 0.0 µg/L  0.0   0.0 
single  3 15 mg/kg  3 hrs 18.97    2.30  2.24 
exposure**    6 hrs 31.87  1.97  0.96 
       9 hrs 18.06  1.58  2.14 
   3 20 mg/kg  3 hrs 44.13   2.90  1.02 
    6 hrs 26.27    2.84  1.08 
9 hrs 22.56  2.34  0.30 
 
Long-term 9 Control   wks 0.0 µg/L  n.d.  0.0 
single    9 3 mg/kg  2 wks 0.60 ± 0.66   0.508 
exposure***    3 wks 2.05 ± 1.88   0.496 
      4 wks 0.34 ± 0.03   0.302 
   9 10 mg/kg  2 wks 2.06 ± 0.17   0.367 
3 wks 2.40 ± 0.71   0.367 
4 wks 2.07 ± 0.85   0.237 
 
*Number of animals per group per dose was 3. The number of animals was prescribed by the Animal Ethical 
Committee. 
**Urine samples were collected at 3, 6 and 9 hours after injection. For this reason total arsenic was measured as 
total arsenic excreted in the urine portion.   
***Total arsenic was measured in 24-hour urine  
n.d. = not detectable  (As <5 µg /l) 
 
 
Protein degradation 
The protein analysis showed changes in the protein composition of the sciatic nerve. Two 
proteins in sciatic nerve fibroblasts (40 and 140 kDa) disappeared in rats treated with the 
highest dose of 20-mg/kg arsenite in comparison to the 15-mg/kg dose group and the 
controls, as can be seen in SDS-PAGE (Figure 2). However, the conclusive evidence of 
protein composition changes was obtained from western blot analysis.
This showed the gradual disappearance of NF-L and NF-M after short-term exposure (Figure 
3). As described in the Materials and Methods section, fibroblast protein bands are 
determined through side-by-side comparison in SDS-PAGE (data not shown) of primary 
fibroblasts in culture and homogenized sciatic nerves from the rat. Furthermore, the same 
separation gels of fibroblast and sciatic nerve homogenates were checked with Western blot 
analysis for presence of neurofilament proteins. It was apparent that fibroblasts grown in 
culture do not contain any neurofilament proteins (data not shown). 
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Figure 2.  Coomassie staining of three sciatic nerve protein homogenates with various arsenic doses. A high 
dose of 20-mg/kg arsenite results in disappearance of fibroblast band sizes of 40 and 140 kDa as indicated by 
the arrows. However these bands are still present in lower dose group and the controls. 
 
Neurofilament proteins gradually disappear after i.v. injection of AsIII, as is shown in Figure 
3A.  NF-L has almost totally disappeared after 9 hours in both dose groups treated with 15- 
and 20-mg/kg arsenite. Figures 3B and 3C show the intensity of the Western blot signals. 
After 3 hours NF-L reaches almost the same signal as its background in both dose groups. 
NF-M shows a decrease in intensity in both cases after 6 hours. NF-H appears to be 
unaffected in the 15-mg/kg-dose group; however, it diminishes in the 20-mg/kg-dose group 
after 9 hours. 
 
 
(A) 
 
   
(B)      (C) 
 
Figure 3 (A) Western blot analysis of NF-H, -M and –L of rats sciatic nerves. The changes in cytoskeletal 
proteins are followed in time, measured up to 9 hours and compared to their control (C). The short-term effect 
of 15- and 20-mg/kg arsenic results in gradual disappearance of primarily NF-L. The effect is more profound in 
the 20-mg/kg dosage than the 15-mg/kg dosage. (B and C) The mean intensity signals of various neurofilament 
protein bands derived from fig 3A. Fig 3B shows the mean intensity of NF-H, -M and -L belonging to 15-
mg/kg doses. Signal reduction in NF-L can be seen as a result of exposure duration.   
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The long-term effect of arsenite on sciatic nerve proteins in lower doses of 3 and 10 mg/kg is 
shown in Figure 4. No significant changes appear in the protein composition in the Western 
blot analysis of neurofilament proteins. The signal intensity of NF-H remains constant at all 
times in both dose groups. This applies also for neurofilament-M and –L (NF-M and NF-L). 
The same is also true in the long-term 15-mg/kg AsIII dose group (data not shown), in which 
neurofilaments did not show any sign of degradation.  
 
 
 
Figure 4.  Western blot analysis of NF-H, -M and –L of rats sciatic nerves. The changes in cytoskeletal proteins 
are followed in time, measured up to 4 weeks and compared to their control (C) The long-term effect with 
lower doses namely 3- and 10-mg/kg arsenic show no significant effect. 
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Discussion  
 
The gain in body weight is used as a parameter for general health; a decrease in body weight 
gain is considered a toxic effect of arsenite in the long term, single exposure part of the 
study. Reduced body weight gain is the result of arsenite administration, whereby the 10-
mg/kg dose group lags behind in their growth in comparison to the 3-mg/kg dose group and 
the control group. After 3 weeks, however, the body weight in the 3-mg/kg single dose group 
was the same as in the control group. The effects of arsenic on body weight are most 
probably a result of reduced food intake due to a decrease in overall health and to the 
observed gastrointestinal tract toxicity (diarrhea) rather than a direct effect of arsenic on 
hypothalamic function. 
Urine samples for measurement of As elimination in the long-term, single exposure group 
were collected during 24 hours (Table 1). The 3-mg/kg dose group excreted 0.60 to 2.05 mg 
As/mmol creatinine and the 10-mg/kg dose group showed an arsenic excretion between 2.06 
and 2.40 mg As/mmol creatinine. The high concentration of 2.05 mg As/ mmol creatinine in 
the long-term, single exposure group is the result of a small urine volume with high arsenic 
content. In contrast to the long-term single exposure, the short-term single exposure group 
shows a much higher excretion, ranging between 18.06 and 31.87 mg As/mmol creatinine for 
the 15-mg/kg dose and 22.56 to 44.13 mg As/mmol creatinine for the 20-mg/kg dose. The 
difference between the long- and short-term studies is the result of the variation in dose range 
and the duration of urine collection. Rats in the short-term experiment received a much 
higher dose of 15- and 20-mg/kg arsenite as compared with 3- and 10-mg/kg arsenite in the 
long-term group. It is likely that in the first few hours after injection, rats excrete most of the 
arsenic dose, either methylated or not, in the urine. This suggests that the arsenic 
concentration in urine toward the end of the 24-hour period of urine collection is diminished. 
This is also observed in the 20-mg/kg dose group. In the 15-mg/kg dose group, the amount of 
excreted arsenic after 3 hours is not as high as in the 20-mg/kg dose group.  
The blood arsenic concentration in the 15-mg/kg dose group drops from 2.30 at 3 hours to 
1.58 mg/l at 9 hours; in the 20-mg/kg dose group a decrease of 2.90 at 3 hours to 2.34 mg/l at 
9 hours is observed. The calculated half-life time (T1/2) in both dose groups is 11 and 17 
hours, respectively. Furthermore, the calculated relative volume of distribution (VD) in both 
dose groups is 5.62 and 6.15 L/kg, respectively, indicating a high degree of tissue binding.  
The amount of arsenic retrieved in the sciatic nerve tissue is inversely related to its 
corresponding dose increase: 2.24 µg/g tissue at 15-mg/kg dose group after 9 hours in 
comparison to 0.30 µg/g tissue at 20-mg/kg dose group. The increase in arsenic doses leads 
to the disappearance of NF-M and NF-L proteins in a time-dependent way. Parallel to this 
remarkable observation, all 3 neurofilament proteins in the sciatic nerves disappear in the 20-
mg/kg dose group after 9 hours. A possible explanation for this observation may be that NF-
M/L proteins encapsulate most of the arsenic through covalent binding with their sulfhydryl 
groups. This would suggest that the dramatic reduction of the arsenic content measured in 
sciatic nerves is the result of the arsenic-induced degradation of NF-M/L proteins and the 
subsequent release of arsenic from sciatic nerves into the circulation and other (much larger) 
body compartments.  
This study demonstrates the effects of arsenite on the composition of peripheral nerve 
proteins, namely neurofilament and fibroblast proteins in sciatic nerve. Fibroblast proteins 
with approximate band sizes of 40 and 140 kDa degraded after a high dosage, as shown in 
Figure 2. Interestingly, this indicates an all-or-none effect, which occurs between 15 and 20 
mg/kg. In the lower dose of 15-mg/kg and the control protein homogenate no changes are 
visible in the Coomassie Brilliant Blue stained gels. It is clear that a higher dose of arsenite 
resulted in a stronger effect on NF-L and some effect on NF-M. An effect of arsenite on NF-
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H is only visible after 9 hours in the highest dose group, 20-mg/kg. In this experiment, it 
became clear that the Wistar rats do not survive a 20-mg/kg dose after 24 hours. The fact that 
NF-H begins to disappear 9 hours after injection could be the result of metabolism and body 
failure just before dying rather than a direct effect of sodium arsenite. 
Our data may indicate intraspecies variation in susceptibility.  In our experiment, all rats 
(Wistar strain) died within 24 hours after iv arsenite injection.  This is in contrast to the 
findings from a previous study using Sprague-Dawley rats, which seem to be more resistant 
to arsenic.8 This has also been found by Todorov (oral presentation on 21.05.2004). 
However, this difference is most likely due to differences in administration route, as in the 
latter study arsenic was administered orally and thus the dose (and dose rate) may have been 
attenuated. 
Our results demonstrate the capacity of arsenic as a neurotoxin, but do not allow conclusions 
on its molecular mechanism. It has been established that arsenite has a high affinity for 
sulfhydryl groups, and it may substitute for phosphate and disrupt oxidative phosphorylation 
by replacing phosphoryl with less stable arsenyl compounds.8 Sulfhydryl (-SH) groups are 
abundantly present in cysteine-containing proteins. Arsenic interacts with -SH groups in their 
reduced form through covalent binding. Since a sufficiently high arsenic dose resulted in 
gradual disappearance of NF-M and NF-L (Figure 3A) and assuming that arsenite is the 
direct cause of protein degradation, it may be concluded that the NF-L is one of the main 
proteins involved in arsenic interaction with its reduced -SH groups. Confirmation of this 
hypothesis can be deduced from the arsenic content of sciatic nerves. The inverse 
relationship between dose and effect in the case of the 20 mg/kg arsenite group in 
comparison to the other groups can be explained through the fact that the arsenic decrease is 
due to degradation of NF-L/arsenic complex leading to disappearance of arsenic from the 
sciatic nerve. NF-L has been reported to act as a linking protein in conjunction with NF-H/-
M and its role in assembly of NFs and maintenance of axonal caliber.24 NF-H and NF-M 
contain 5 and 2 cysteine groups, respectively, whereas NF-L contains only one. NF-L is the 
most predominant protein in neurofilaments. One potential mechanism of NF-L binding to 
other protein molecules is through disulfide bridge formation. Arsenic may uncouple 
disulfide bridges in NFs, leading to a complex of As with two cysteine groups in the same 
molecule or in two neighboring proteins.  
If axonal degeneration of protein is not directly related to interaction of arsenite with 
sulfhydryls, another probable cause could be the calcium-mediated degradation of 
neurofilament proteins.25 It is possible that arsenic affects the calcium movement and 
distribution, which in turn could result in protein degradation. The question would be why 
proteins like NF-L are more susceptible to degradation by calcium-mediated protein 
degradation than others such as NF-H.   
Phosphorylation of NFs proteins may be another target for arsenic in addition to sulfhydryl 
groups. Changes in cytoskeletal protein composition are related to NF phosphorylation.26 All 
3 phosphorylated NFs proteins tend to accumulate in the cell body.24,27 This possible effect 
of arsenic on phosphorylation may play an additional role in neuropathy. 
There are different causes of peripheral neurotoxic injury involving metals as neurotoxins: 
neuronopathy, axonopathy and myelinopathy.13 The mechanism suggested above is in 
agreement with axonopathy. In addition to this possible mechanism, other possibilities are 
feasible instead of, or in addition to, our proposed mechanism. Arsenic may affect cell body 
function, which could lead either to accumulation of NF fragments in the cell body, or to 
inhibited production. Both possibilities would lead to a decrease of cytoskeletal proteins in 
the axons. However, if this were true, one would expect a much slower onset of NF-L 
reduction than the actual results after only 3-9 hours dosing. Neuronopathy as basis for 
Chapter 3 
 42 
arsenic-induced peripheral neuropathy is probably unlikely. There is more research needed to 
definitively exclude neuronopathy as the basis for As-induced peripheral neuropathy. 
The present set of experiments does not allow the conclusion that arsenic is not a 
myelinotoxin. However, myelinopathy as cause of arsenic-induced peripheral neuropathy is 
not likely, given the rapid response of NF-proteins to arsenic exposure.  
In arsenic-exposed patients neurophysiological abnormalities have been described 
extensively.8 Both sensory and motor conduction velocity can be decreased. Recently, 
Dubois et al.28 demonstrated that motor functions in mice with the deleted Nefl gene were 
impaired. These authors concluded that NF-L plays an essential part in motor function. These 
findings corroborate our conclusions that decrease in NF-L is a sensitive parameter of the 
peripheral nervous system for arsenic toxicity. 
We have been able to demonstrate a neurotoxic effect of arsenic in rats. Future studies to 
elucidate the mechanism of arsenic neurotoxicity are in progress.  
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Abstract 
In our previous study in rats acutely exposed to As, we observed an effect of As on 
neurofilaments in the sciatic nerve.  This study deals with the effects of inorganic As in 
Wistar rats on the cytoskeletal protein composition of the sciatic nerve after subchronic 
intoxication. Sodium meta-arsenite dissolved in phosphate-buffered saline (PBS) was 
administered daily in doses of 0, 3 and 10 mg/kg body weight/day (n = 9 rats/group) by 
intragastric route for 4, 8 and 12 week periods. Toxicokinetic measurements revealed a 
saturation of blood As in the 3- and 10-mg/kg dose groups at approximately 14 µg/ml, with an 
increase in renal clearance of As at increasing doses. After exsanguination, sciatic nerves 
were excised and the protein composition was analyzed. Analysis of the sciatic nerves showed 
compositional changes in their proteins. Protein expression of neurofilament Medium (NF-M) 
and High (NF-H) was unchanged. Neurofilament protein Low (NF-L) expression was 
reduced, while µ- and m-calpain protein expression was increased, both in a dose/time 
pattern. Furthermore, NF-H protein was hypophosphorylated, while NF-L and microtubule 
associated protein tau (MAP-tau) proteins were (hyper)-phosphorylated. In conclusion, we 
show that expression of µ- and m-calpain protein is increased by exposure to As, resulting in 
increased NF-L degradation. In addition, hyperphosphorylation of NF-L and MAP-tau by As 
also contribute to destabilization and disruption of the cytoskeletal framework, which 
eventually may lead to axonal degeneration.  
 
 
 
Keywords: arsenite, calpain, neurofilament, microtubule associated protein tau, neurotoxicity, 
phosphorylation 
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1. Introduction 
As is a semi-metalloid element that occurs naturally in our environment. Throughout history, 
As has been used as a pesticide, herbicide, homicide or suicide agent in Chinese medicine and 
as make-up in eye shadows in the Roman era. Nowadays, millions of people in South East 
Asia (Rahman et al., 2001) and several South American countries are daily exposed to As due 
to contaminated drinking water with considerable adverse public health effects. 
Worldwide, chronic intoxication with As is a much bigger problem in comparison to acute 
intoxication (Centeno et al., 2002). As intoxication, whether acute (Greenberg, 1996) or 
chronic, leads to peripheral neurotoxicity, which to date has only been demonstrated clinically 
and in controlled electrophysiological studies (Le Quesne and McLeod 1977; Goebel et al., 
1990). Neurotoxic effects have been reported in many cases, although PNS impairment is 
common in As-exposed populations (Hafeman et al., 2005). Peripheral neuropathy, 
manifested by decreased sensibility, ataxia, pain and paresis are common neurological 
symptoms of As intoxication, which often begins in the lower extremities. Although PNS 
impairment is common in As-exposed populations (Goebel et al., 1990; Greenberg, 1996; 
Lagerkvist and Zetterlund, 1994), its mechanism has hardly been studied. 
Nerve cytoskeletal proteins form a flexible framework for the cell, provide attachment points 
for organelles and formed bodies, and enable the possibility of communication between cell 
parts. The major protein constituents of the cytoskeleton are microtubule and microtubule-
associated proteins (MAPs), intermediate filaments and microfilaments. The intermediate 
filaments are subdivided into three types of neurofilaments that are specific to the nervous 
system: NF-H, NF-M and NF-L, according to their molecular weight of 200, 150 and 68 kDa, 
respectively. Neurofilaments are the major component in large myelinated neurons. Several 
studies have shown that changes in neurofilament proteins and MAP-tau are related to many 
neurodegenerative diseases, such as Alzheimer’s (Dowjat et al., 2001; Trojanowski et al., 
1993), diabetes (Schechter et al., 2005), amyotrophic lateral sclerosis (Lariviere and Julien, 
2004) and the Guillian-Barré syndrome (Winship, 1984). 
MAP-tau promotes tubulin assembly in microtubules; although tau proteins are found in all 
cells, they form the major components of neurons and are predominantly associated with 
microtubules of the axon. In the brains of patients with Alzheimer’s disease the neuronal 
cytoskeleton is progressively disrupted and replaced by tangles of paired helical filaments 
(PHFs), which are composed mainly of hyperphosphorylated forms of tau proteins (Alonso et 
al., 1996). NF-L has been shown to be essential in filament assembly (Zhu et al., 1997); 
furthermore, mice with the deleted Nefl gene demonstrated impaired motor functions (Dubois 
et al., 2005).  In a previous study we showed that after a single acute exposure to As, the 
protein composition of the sciatic nerve in rats, especially NF-L, was affected immediately 
(Vahidnia et al., 2006), while also delayed effects occurred, whereby NF-M and NF-L 
proteins decreased dose dependently over time after a single exposure to arsenite.  
Neurodegenerative diseases result from deterioration of neurons, caused by functional 
disturbances and/or pathological changes in the peripheral nervous system (Miller et al., 
2002). NF and tau proteins compete for the same microtubule binding site. Phosphorylated 
NFs have diminished affinity to the microtubule. Hyperphosphorylation of tau and 
neurofilament may underlie the cytoskeletal abnormalities and neuronal death seen in several 
neurodegenerative diseases including Alzheimer's disease (AD) (Alonso et al., 1996). Tau 
protein, in its hyperphosphorylated form, is the major component of PHF and neurofibrillary 
tangles and in plaques in Alzheimer's disease brain. 
In this study, we study in Wistar rats the effects of inorganic As on the cytoskeletal protein 
composition of the sciatic nerve after subchronic intoxication. Sodium meta-arsenite solution 
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dissolved in PBS was administered daily by gavage to the rats at dose levels of 0, 3 and 10-
mg/kg body weight/day (n = 9 rats/group) for 4, 8 and 12 weeks. The present research, which 
is a follow-up to a previous study (Vahidnia et al., 2006) aims at investigating the semi-
chronic effects of arsenite on rat sciatic nerve proteins after repeated exposure in order to 
introduce a better comparison model for the human situation as regards the peripheral 
axonopathy and the pathological changes in the peripheral nervous system. It is the purpose of 
this study to investigate the effects of As on the peripheral nervous system as a step forward 
to understanding the mechanism of As neurotoxicity. 
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2. Materials and Methods 
 
2.1. Chemicals.  
 
Sodium meta-arsenite (NaAsO2: As
III) (product no. 22,869-9, 98% pure) and acrylamide/bis-
acrylamide (product no. A 3699, Mix ratio 37.5:1, T30%, C2.6%) and color markers high 
range (HMW color marker) (product no. C 3312) were purchased from Sigma-Aldrich (St. 
Louis, Missouri, USA). TEMED (catalog no. 161-0800) and sodium dodecyl sulphate 
(catalog no. 161-0301) were purchased from Bio-Rad (Veenendaal, Netherlands). Tris-HCl 
(catalog no. 108219) and EDTA (catalog no. 108418) were purchased from Merck 
(Darmstadt, Germany). BCATM Protein Assay Kit (Pierce, product no. 23225. Rockford, IL 
USA) was obtained from Pierce (Rockford, USA). Phosphate-buffered saline (PBS, NaCl 145 
mmol/l, phosphate 1.4 mmol/l and pH 7.5) was prepared from analytical grade reagents by the 
Department of Pharmacy. Kodak biomax XAR film (catalog no. 165 1454) was obtained from 
Kodak (Shelton, CT, USA). ECL plusTM Western blotting detection reagent was obtained 
from Amersham Biosciences (Piscataway, NJ, USA). Mouse anti-NF-90 antibody to all three 
neurofilament proteins (NF-H, NF-M and NF-L) was a gift from Prof. E. Marani of the 
Department of Neurosurgery at the Leiden University Medical Center, Netherlands (Oudega 
et al., 1996). Mouse anti-tau monoclonal antibody, Clone Tau 46 (catalog no. Ab24747) to the six 
isoforms and mouse monoclonal antibody to Phosphoserine/threonine/tyrosine (catalog no. 
Ab15556) and monoclonal antibody to GAPDH (catalog no. Ab8245) were obtained from 
Abcam (Cambridge, United Kingdom). Rabbit polyclonal anti-Calpain (H-60) (catalog no. sc-
30065) was purchased from Santa Cruz biotechnology, inc. (Califorina, USA). 
 
2.2. Animals and housing.  
 
Male Wistar rats (225-250g) were obtained from Charles River, Maastricht, Netherlands. The 
rats were acclimatized for 7 days and housed in 9 groups of 3 in plastic cages on sawdust in a 
12/12 h light/dark cycle. The rats were fed a standard diet and tap water ad libitum in their 
plastic and metabolic cages. The protocol for this study was submitted to and agreed by the 
Animal Ethical Committee of the Leiden University Medical Center. 
 
2.3. Experimental design.  
 
The rats received sodium arsenite solution in PBS once daily by gavage. 0, 3 and 10 mg/kg 
AsIII (NaAsO2) levels of dose were used for n=3 rats per time index of 4, 8 and 12 weeks per 
dose (n=9 rats/dose group). The highest dose, 10 mg/kg, is four times lower in dosage 
intensity than the LD50 of 41 mg/kg that is indicated by the manufacturer for sodium meta-
arsenite. The administered volumes ranged from 0.25 to 0.45 ml depending on body weight. 
The control groups were intubated with PBS 1µl/g body weight, so a rat with 250 gram body 
weight received 0.25 ml of PBS without added arsenite. This semi-chronic experiment was 
divided in 3 periods of 4, 8 and 12 weeks. Urine samples were weekly collected in plastic 
containers at the same time and during the individual housing of each rat in a metabolic cage 
for 6, 8 and 10 hours for the 0-, 3- and 10-mg/kg dose groups, respectively. The As-treated 
rats were kept longer in the metabolic cages in order to collect sufficient urine for analysis. 
After the intended duration of 4, 8 or 12 weeks, the rats in a plastic sealed cage with in- and 
out-flow tubes were anesthetized individually with isoflurane. Subsequently, they were 
exsanguinated by means of arterial blood withdrawal from the inferior mesenteric artery.  
Nervus ischiadicus (sciatic nerve) arises from sacral plexus and passes about halfway down 
the thigh where it divides into the common peroneal and tibial nerves. The nerve is dissected 
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on one end from the sacral plexus as close as possible to the spinal column and on the other 
end just before its division. The nerve of each leg is dissected by about 2cm. In these 
experiments the sciatic nerve from the right leg is used for protein analysis and the one from 
the left leg is used for As measurement. 
 
2.4. Arsenic analysis.  
 
Urine samples for the measurement of As elimination were collected weekly at the same time 
for 6, 8 and 10 hours for the 0-, 3- and 10-mg/kg dose groups, respectively, by placing the rats 
in metabolic cages. 
The blood samples for As analysis obtained at the end of the exposure period were first 
digested in an acid mixture comprising one part perchloric acid and one part nitric acid (1:1) 
(digestive acid). Fifty µl bloods were added to 950 µl of digestive acid and incubated for 1 hr 
at 70 °C. The sciatic nerve samples were weighed and digested in 1 ml digestive acid as in 
blood and incubated for 1 hr at 70 °C.  The urine samples of the highest dose groups were first 
diluted 200 times with Milli-Q water (MQ-H2O). From the digested blood or nerve or the 
diluted urine samples 0.5 ml was added to 4.5 ml of reduction acid consisting of 216 ml MQ-
H2O, 27 ml 37% hydrochloric acid (1M HCl), 6 g sodium iodide (NaI) and 3 g L-(+)ascorbic 
acid (C6H8O6) and incubated for 1 hr at 70 °C.  
The As content of urine, digested blood and digested sciatic nerve was measured with atomic 
absorption spectrometry (Perkin-Elmer FIAS-3100 AAS). The technique for measuring total 
As content is hydride generation coupled to AAS (HG-AAS). An As electrodeless discharge 
lamp of 7W was used; As absorption was measured at 193.7 nm. The matrix of the calibration 
solution for urine consisted of 4.5 ml 1M HCl and 0.5 ml As standard solution dissolved in 
MQ-H2O ranging from 0 µg/l to 200 µg/l end concentration. Where the digested blood and 
nerves are concerned, the matrix of the calibration solution comprised 4.5 ml 1M HCl and 0.5 
ml of As standard solution dissolved in digestive acid ranging from 0 µg/l to 200 µg/l end 
concentration.  
 
2.5. Protein sample processing and analysis.  
 
The three neurofilament proteins (NFs) and MAP-tau expression and phosphorylation were 
analyzed by using Western blot technique. Excised sciatic nerves weighing 12.5 mg to 18.5 
mg were homogenized with a blender in a 1.5 ml Tris-HCl buffer (200 mM, pH 8.0), also 
containing EDTA 3 mM and sodium dodecyl sulphate (SDS) 1% w/v. SDS was added to 
inactivate enzymes by disrupting the non-covalent bonds.  The nerve tissues were 
homogenized on ice for 2 minutes and subsequently heated for 5 minutes at 100ºC. The 
homogenization and heating procedure was repeated twice. The homogenized samples were 
centrifuged for 1 min at 10,000xg and the supernatant was transferred to a new 1.5 ml 
eppendorf tube. Protein concentrations of the homogenates were measured by the BCATM 
Protein Assay Kit. To obtain the same protein concentrations prior to analysis by SDS-PAGE, 
the nerve homogenates were standardized with Tris-HCl buffer. Nerve homogenates were 
analyzed on an 8% acrylamide separation gel (Laemmli, 1970). The separation gels were used 
for immunoblotting on 0.2 µm nitrocellulose membranes in conjunction with polyclonal 
neurofilament antibodies to all 3 neurofilament proteins: NF-H, NF-M and NF-L, monoclonal 
antibody against MAP-tau and monoclonal antibody against phosphoserine/threonine/tyrosine 
and monoclonal antibody against GAPDH as loading control for SDS-PAGE. Application of 
the ECL plusTM Western blotting detection reagent and the 30-seconds to 3-minutes 
exposure to Kodak biomax XAR film concluded the Western blot analysis. The western blot 
analysis of the same samples was performed in triplicate. The band intensities on the Kodak 
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biomax XAR film were analyzed by Quantity One – Densitometer GS-710 from Bio-Rad 
(Veenendaal, Netherlands). 
Although monoclonal antibody against phosphoserine/threonine/tyrosine is not specific for 
NF and tau proteins, the positions of NF’s and tau proteins were determined through side-by-
side comparison, digitally. The nitrocellulose blots for NFs and tau were aligned with those in 
the anti-phospho blot. High molecular weight Color marker proteins on all blots were used as 
reference points to align the phosphorylated protein bands, for comparison with protein 
expression bands.   
 
2.6. Statistical analysis.  
 
The arsenic biokinetics in body fluids, nerve tissue data and western blot analysis were 
statistically evaluated for each dose group using the SPSS 14.0 for Windows. Analysis of 
variance (ANOVA) for means was carried out to evaluate the data in. A level of p<0.05 was 
accepted as statistically significant. 
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3. Results 
 
3.1. General health 
 
Increase in the AsIII dose results in a decrease in body weight gain (Fig. 1). The difference 
between weight gain in control rats and the reduced weight gain in rats treated with 10 mg/kg 
AsIII becomes evident after 2 weeks (p<0.001). Furthermore, in both dose groups, diarrhea, 
which is also a symptom in acute As poisoning, was observed. The 3 mg/kg AsIII doses also 
resulted in diminished appetite and reduced general alertness. Body weight in the 3-mg/kg 
dose group increased to such extent that there was no significant difference between treated 
and control animals. 
 
 
 
Fig. 1. Body weight increase in three different dose groups of the 12-week exposure group. Each dose group of 
0, 3 and 10 mg/kg consists of 3 rats, which were exposed to As and monitored over 12 weeks. The highest dose 
group of 10 mg/kg lags behind. ANOVA for mean value per dose group showed significant difference of  
p<0.001. 
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3.2. Arsenic distribution and elimination 
 
The total amount of As excreted in urine was measured and expressed as µg/ml (Table 1). The 
As concentration in urine of 3-mg/kg dose group increased from 8.57 ± 1.52 µg/ml to 13.65 ± 
0.95 µg/ml after 4 weeks and 12 weeks, respectively. In the 10-mg/kg dose group, the As 
concentration in urine increased from 36.6 ± 10.73 µg/ml to 55.8 ± 59.45 µg/ml after 4 weeks 
and 12 weeks, respectively. The As excretion in urine was also calculated in relation to the 
creatinine content (Fig. 2). The 3-mg/kg dose group showed a parallel progress to the control 
group, with only a slight elevation. However, the 10 mg/kg dose group showed a proportional 
increase from the start up to the last week. 
 
 
 
Fig. 2. As excretion, measured weekly as the amount of As (mg) excreted in urine expressed per mmol 
creatinine. ANOVA for mean value per dose group showed significant difference of p<0.001. 
 
Table 1 shows the As concentration in blood (µg/ml). The As content of blood was saturated 
by approximately 14 µg/ml after 4 weeks in both 3- and 10-mg/kg group.  
The As content of the sciatic nerve was measured and expressed in µg/g. In the control 
groups, the As content was between 0.02 ± 0.01 and 0.08 ± 0.02 µg/g tissue. The 3-mg/kg 
dose group showed a decrease in As content from 0.43 ± 0.25 µg/g tissue to 0.35 ± 0.24 µg/g 
tissue after 4 and 8 weeks, respectively and a decrease to 0.11 ± 0.01 µg/g tissue after 12 
weeks, whereas the 10-mg/kg dose group showed an As decrease from 1.17 ± 0.23 µg/g tissue 
to 0.53 ± 0.20 µg/g tissue after 4 and 8 weeks, respectively, and a decrease to 0.89 ± 0.15 
µg/g tissue after 12 weeks. 
The volume of distribution (VD) (l/kg) was calculated from the As content measured in the 
nerve tissue (µg/g) divided by the As content of the blood (µg/ml). The VD in 3-mg/kg dose 
group decreased from 0.043 ± 0.0264 to 0.024 ± 0.0156 after 8 weeks and to 0.008 ± 0.0005 
ml/g after 12 weeks of treatment. The 10-mg/kg dose group also showed a decrease from 
0.106 ± 0.0233 to 0.039 ± 0.0161 after 4 and 8 weeks, respectively, and a decrease to 0.067 ± 
0.0114 ml/g after 12 weeks. 
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3.3. Expression of the cytoskeletal proteins 
 
The protein expression analysis showed As-induced changes in the protein composition of the 
sciatic nerve. Western blot analysis showed no apparent changes in the NF-H and NF-M 
during the 12-week time window and increased dosage. However, the NF-L protein content 
was significantly decreased in the 3- (p<0.05) and even more so in the 10-mg/kg dose group 
(p<0.01) (Fig. 3). However, the microtubule-associated protein tau showed no significant 
changes in its expression. 
 
 
  
3A.      
         
3B.      3C. 
 
Fig. 3. 3A. Western blot analysis of the expression levels of the three-neurofilament proteins and total-tau of the 
sciatic nerve in the three dose groups in relation to time after dosing. Figure 3B and C. show the densitometry 
measurements in relative mean values (± SD) after 4, 8 and 12 weeks exposure for the number of performed 
western blots (n=3). ANOVA showed a significance of p<0.01 (*) for decrease in NF-L expression.  
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3.4. Calpain protein expression in sciatic nerves 
The analysis of µ- and m-calpain protein expression in As-treated rats showed significant 
increase with time for µ-calpain (p<0.01) and m-calpain (p<0.05) in both the 3- and the 10-
mg/kg dose group (Fig. 4). 
 
 
   
  
 
4A.       
 
   
4B.      4C.   
 
Fig. 4. 4A. Western blot analysis of the expression levels of the µ-calpain and m-calpain proteins of the sciatic 
nerve in the three dose groups in relation to time after dosing. Figure 4B and C. show the densitometry 
measurements in relative mean values (± SD) after 4, 8 and 12 weeks exposure for the number of performed 
western blots (n=3). ANOVA showed a significance of p<0.01 (*) for increased µ-calpain expression and p<0.05 
(*) for m-calpain expression. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 58 
3.5. Phosphorylation of cytoskeletal proteins 
 
Phosphorylation of various proteins was made visible by using antibodies against the hydroxy 
amino acids in proteins (Fig. 5). Phosphorylation of NF-H shows for the 0-mg/kg dose group 
a decrease in time from 4 to 12 weeks. For the 3-mg/kg dose group, the total phosphorylation 
level is lower than that of the control groups; however, in the dose group itself, 
phosphorylation level is increased from 4 to 12 weeks (p<0.05). The 10-mg/kg dose group 
shows the same phosphorylation pattern as the 3-mg/kg dose group but with a higher 
intensity. 
The NF-M protein shows no significant phosphorylation on their serine, threonine or tyrosine 
amino acid groups, with or without arsenite. However, the NF-L and the MAP-tau proteins 
are more phosphorylated in the 3- and 10-mg/kg dose groups. The NF-L protein is 
hyperphosphorylated in both the 3- (p<0.05) and the 10-mg/kg dose group (p<0.001). The 
MAP-tau protein is also hyperphosphorylated in both the 3- (p<0.01) and the 10-mg/kg dose 
groups (p<0.001). 
 
 
   
5A.       
 
   
5B.      5C.   
 
Fig. 5. 5A. Western blot analysis of four sciatic nerve proteins visualized with antibody against 
phosphoserine/threonine/tyrosine. Figure 5B and C. show the densitometry measurements in relative mean 
values (± SD) after 4, 8 and 12 weeks exposure for the number of performed western blots (n=3). ANOVA 
showed a significance of p<0.05 (*) for decrease in NF-H and p<0.001 (*) for increase in NF-L and MAP-tau 
phosphorylation. 
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4. Discussion 
 
Reduction in body weight gain is used as a parameter for the decrease in the rats’ general state 
of health. Rats treated with 3 mg/kg arsenite show no changes in body weight gain, unlike the 
control groups treated with PBS only. However, after the first week and significant lagging 
behind over the course of time, the 10-mg/kg dose group shows a decrease in body weight 
gain in comparison to the 0- and 3-mg/kg dose groups (Fig. 1). The effects of As on body 
weight are most probably a result of reduced food intake as a result of decrease in general 
health and of the observed gastrointestinal tract toxicity (diarrhea) rather than a direct effect 
of As on hypothalamic function. 
Urine samples for the measurement of As elimination were collected as described in 2.3., 
Experimental design (Table 1). The 3-mg/kg dose group showed a gradual increase in As 
excretion from 8.57 (4 weeks) to 13.65 (12 weeks) mg As/l. The As excretion in the 10-mg/kg 
dose group was much higher, starting from 36.6 mg As/l after 4 weeks to 55.8 mg As/l after 
12 weeks of treatment. The high As concentration in the 10-mg/kg dose group is the result of 
a significantly decreased diuresis in the 3-mg/kg (p<0.01) and the 10-mg/kg dose group 
(p<0.05). This drop in diuresis is most probably the result of diarrhea in both dose groups. As 
can be seen from Table 1, renal clearance of As is increased in time and also clearance is 
higher in the 10-mg/kg dose group than the 3-mg/kg dose group, in spite of reduced diuresis. 
This is also emphasized in Fig. 2, where renal excretion is shown as mg As excreted per mmol 
creatinine, whereby the 10-mg/kg dose group shows the highest increase (p<0.01) in 
comparison to the 0- and the 3-mg/kg dose groups.   
The blood As concentration in both 3- and 10-mg/kg dose groups increased from 4 to 8 weeks 
(p<0.001) and leveled off as from the 8th week due to approximately 14 µg/ml As 
concentration. The 3- and 10-mg/kg dose groups show no difference in As levels at all three 
times.  From the renal clearance of As in both dose groups, it can be seen that the As blood 
concentration is maintained at a maximum level by enhanced renal excretion. The mechanism 
of this apparent homeostasis is not clear as yet. 
The amount of As measured in the sciatic nerve tissues of the 3-mg/kg dose group is higher in 
comparison to the controls (p<0.001). However, the measured concentrations diminished 
from 0.43 ± 0.25 µg/g As after four weeks exposure to 0.11 ± 0.01 µg/g As (p<0.001 ) in the 
group exposed for twelve weeks. A decrease pattern is also present in the 10-mg/kg dose 
group, but with a higher concentration of 1.17 ± 0.23 µg/g As in the group exposed for four 
weeks, followed by a decrease to 0.53 ± 0.20 µg/g tissue after 8 weeks and a decrease to 0.89 
± 0.15 µg/g tissue after 12 weeks (p<0.001). A possible explanation for this decrease may be 
that on the one hand a decrease in expression levels of NF-L results in less available 
sulphydryl (-SH) groups for As to undergo a covalent binding (Fig. 3). On the other hand, the 
phosphorylation of various proteins by As in the sciatic nerves also results in less available 
binding sites for As (Fig. 5) (Shea et al., 2003).  
The relative volume of distribution (VD) of As in sciatic nerve was calculated from the As 
concentrations in blood and nerve tissue. In comparison with the total body VD (5.62-6.15 
ml/g) (Vahidnia et al., 2006); the VD in nerve tissue is very low, namely 0.043-0.008 ml/g for 
the 3-mg/kg dose group, and 0.106-0.039 for the 10-mg/kg dose group. It should be noted that 
in our previous work, As was administered intravenously and in this study orally. A possible 
explanation of the difference between total body and nerve tissue VDs is that trivalent As has a 
high affinity for reduced sulphydryl (-SH) groups. Orally administered arsenite is metabolized 
in the liver before entering the circulation, whereas intravenously administered arsenite is 
more readily available to interact with reduced sulphydryl (-SH) groups.  
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This study demonstrates the effects of orally administered arsenite on the composition of 
sciatic nerve proteins, namely MAP-tau and NFs. As shown in Fig. 3, there are no apparent 
changes in the expression levels of MAP-tau, NF-H and NF-M proteins. However, NF-L 
expression is gradually decreased in the 3-mg/kg dose group from 4 to 8 and to 12 weeks. The 
decrease is more apparent in the 10-mg/kg dose group (p<0.01), which demonstrates that the 
NF-L decrease depends on the dose and exposure time. The decrease of NF-L expression 
found in this study may play an important role in As-induced pathological changes of the 
peripheral nervous system, since NF-L is the only NF protein capable of organizing and co-
assembling filaments on its own in vivo. NF-H and NF-M each need an NF-L protein to form 
a heteropolymer (Carpenter and Ip, 1996). Thus far, it can be concluded that the decrease in 
NF-L expression caused by arsenite results in less available NF-L for the formation of 
heteropolymer in the cytoskeletal framework. This decrease in NF-L expression is possibly a 
post-translational activity as a result of a proteolytic process, since in vitro studies with iAsIII 
in neuroblastoma (SK-N-SH) and Schwannoma (ST-8814) cell lines show no effect on the 
mRNA expression level of cytoskeletal genes (Vahidnia et al., 2007). Calpain is calcium-
activated cytoplasmic protease that is responsible for NF-L degradation, since neuroblastoma 
cells (SY-5Y) treated with arsenic trioxide (trivalent As) show an increase in intracellular 
calcium (Florea et al., 2007). Figure 4 shows an increase of µ-calpain (p<0.01; activated by 
µM amount of calcium) and increase of m-calpain (p<0.05; activated by mM amount of 
calcium) in both the 3- and 10-mg/kg dose groups. Studies in PC12 cells under oxidative 
stress circumstances have shown an increase in calcium within the cells and up-regulation of 
calpain leading to degradation of NF-L protein (Ray et al., 2000). Furthermore, inactivation of 
calpain by calpain inhibitor (MDL-28170) prevents NF-L breakdown (Kunz et al., 2004; 
Lopez-Picon et al., 2006). These results suggest that As-induced destabilization and 
disruption of the cytoskeletal framework is partly due to increased expression of calpain, 
which in turn is responsible for NF-L degradation in a calcium-induced proteolytic process. 
Neurofilament proteins are synthesized exclusively in the cell body of neurons and are 
transported along nerve fibers as part of the slow component of axonal transport (Hoffman 
and Lasek, 1975). Phosphorylation of proteins causes conformational changes in protein 
leading to an altered function or pathological changes in most cases. Neurofilament 
accumulation in the cell body due to hyperphosphorylation is seen in several neurological 
diseases and this phosphorylation is believed to be a regulatory mechanism that controls the 
speed of movement (Miller et al., 2002). Hyperphosphorylated NF-H tends to accumulate in 
the cell body, which would result in disruption of neurofilament transport. As shown in Fig. 5, 
the cytoskeletal proteins in this study have also been affected in various ways by As-induced 
toxicity. It shows the various phosphorylation states of the NF and MAP-tau proteins. As 
mentioned earlier, the NF-H protein expression in the axon remains constant, independent of 
the used dose or exposure time (Fig. 3). However, after exposure to As, the NF-H shows an 
initial reduction in its phosphorylation, which is increased again depending on exposure time 
and increased dose (Fig. 5A). A possible explanation may be that the initial decrease of NF-H 
in axons in the 3-mg/kg dose group is caused by reduced transport of hyperphosphorylated 
NF-H from cell body to axon (Schlaepfer, 1987; Shea et al., 2003). The subsequent increase 
of NF-H in the axon may be explained by combination of minimum transport of 
phosphorylated NF-H in the axons and increased phosphorylation caused by As in the axon 
itself. After administration of 3 and 10 mg/kg As, NF-L and MAP-tau are phosphorylated as 
well. The NF-M protein shows no significant changes in its phosphorylation state. The 
absence of significant NF-M phosphorylation is remarkable, particularly given the similar 
serine, tyrosine and threonine content in the other NF proteins.  
Hence, it can be concluded that the hyperphosphorylated NF-H proteins in the cell body are 
transported to a lesser extent into the axons. NF-L and MAP-tau are both phosphorylated in a 
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dose/time dependant manner in the 3- and 10-mg/kg dose groups, which is not the case with 
the control group. The increase in NF-L phosphorylation (Fig. 5) shows that NF-L is strongly 
phosphorylated, although its total protein expression has decreased at the highest As dose 
(Fig. 3). NFs and MAP-tau proteins can be phosphorylated by a number of serine/threonine 
kinases, such as: glycogen synthase kinase 3 beta (GSK3ß), which is involved in energy 
metabolism, neuronal cell development, and body pattern formation (Plyte et al., 1992), 
cyclin-dependent kinase 5 (Cdk5), and various kinases such as  protein kinase A (PKA).   
In conclusion, we have shown that As interacts with the cytoskeletal structure and the sciatic 
nerve function by affecting the NF phosphorylation state and MAP-tau proteins. 
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Abstract 
 
Neurological studies indicate that the central (CNS) and peripheral nervous system (PNS) 
may be affected by arsenic (As). As-exposed patients show significantly lower nerve 
conduction velocities (NCVs) in their peripheral nerves in comparison to healthy subjects. As 
may play a role in the disruption of neuroskeletal integrity, but the mechanisms by which it 
exerts a toxic effect on the peripheral and central nervous system are still unclear. In the 
present study, we examined the neurotoxic effects of various arsenic metabolites (iAsIII, iAsV, 
MMAV and DMAV) on two different cell lines derived from the peripheral (ST-8814) and 
central (SK-N-SH) nervous system. The effects of the arsenic metabolites were examined on 
the relative quantification levels of the cytoskeletal genes, neurofilament-light (NEFL), 
neurofilament-medium (NEF3), neurofilament-heavy (NEFH) and microtubule associated 
protein-tau (MAPT), using Real-Time PCR. Our results show that iAsIII and iAsV have no 
significant effects on either cell lines. On the other hand, MMAV and DMAV cause significant 
changes in expression levels of NEF3 and NEFL genes, while the expression level of the 
NEFH gene is significantly increased in both cell lines.  
 
 
 
 
Keywords: Arsenic metabolites; Cytoskeletal genes; Gene expression; Neurotoxicity; SK-N-
SH cells; ST-8814 cells.
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1. Introduction 
 
Arsenic is a naturally occurring toxic element, widely distributed in the earth's crust. In large 
parts of the world such as South East Asia (Rahman et al., 2001) and South America 
inorganic Arsenic (iAs) poisoning is a major health concern (Blanco et al., 2006; Ferreccio 
and Sancha 2006). This is mostly due to water pollution from natural sources and soil 
contamination. Arsenic compounds also have a long history of use in medicine, and have 
shown a re-emergence of late with the recent introduction of As trioxide treatment for acute 
promyelocytic leukaemia (Jing  et al., 2001). 
Inorganic arsenic is thought to be the most toxic, while most organic forms of arsenic are 
considered relatively less toxic (Styblo et al., 2000). In many species arsenic metabolism is 
characterized by two main types of reactions: (1) reduction reactions of pentavalent to 
trivalent arsenic, and (2) oxidative methylation reactions in which trivalent forms of As are 
sequentially methylated to form monomethyl- (MM-) and dimethyl- (DM) products: iAsV → 
iAsIII → MMAV → MMAIII → DMAV → DMAIII (Aposhian et al., 1997). 
The neurological manifestations of arsenic exposure are varied. Both the peripheral (PNS) and 
the central (CNS) nervous system can be damaged by acute or chronic exposure. Although 
PNS impairment is common in As-exposed populations (Hafeman et al., 2005), its 
mechanism has hardly been studied. The period of time between start of exposure to As and 
onset of neuropathy symptoms may range from 10 days to 3 weeks after a single dose and 
often resembles the Guillian-Barré syndrome (Winship, 1984). The mechanism by which As 
exerts an effect on the nervous system is unclear, but As neuropathy is thought to be a distal 
axonopathy (De Wolff and Edelbroek, 1994), which may result from derangement of central 
and peripheral nervous system neurons. Axonal degeneration is the probable cause of 
disturbance in nerve conduction velocity (Goebel et al., 1990; Greenberg, 1996). 
Axonal integrity is maintained by three categories of cytoskeletal proteins: neurofilaments, 
which are found in high concentrations along the axons, the microtubules and the actin 
filaments (microfilaments). Neurofilaments are found in high concentrations along the axons 
of vertebrate neurons. Three types of neurofilament proteins exist, which co-assemble in-vivo, 
forming a heteropolymer that contains Neurofilament-Light (NF-L) plus either 
Neurofilament-Heavy (NF-H) or Neurofilament-Medium (NF-M) proteins. During axonal 
growth, new neurofilament subunits are incorporated all along the axons. The level of 
neurofilament gene expression seems to directly control axonal diameter (Hoffman et al., 
1985), which in turn controls how fast electrical signals travel down the axon.  
Microtubules consist of tubulin subunits. Their stability is regulated by their interaction with 
microtubule-associated proteins (MAPs). MAP function includes both stabilizing and 
destabilizing microtubules, guiding microtubules towards specific cellular locations, cross-
linking microtubules and mediating the interactions of microtubules with other proteins in the 
cell. MAP-Tau is a microtubule-associated protein, which is primarily expressed in neurons.  
It is hypothesized that a disruption in neurofilament structure, or in the cross-linking proteins 
that attach the neurofilaments to the microtubules and actin filaments distributed along the 
axon, can result in axonal disorganization and eventually axonal degeneration. In our previous 
study with rats, single exposure to iAsIII (i.v.) demonstrated that axonal cytoskeletal protein 
composition changes, namely that NF-L decreases in a time/dose dependent manner 
(Vahidnia et al., 2006).  
In order to further characterize the effect of As compounds on the neuronal cytoskeleton, we 
examined the effects of As metabolites (iAsIII, iAsV, MMAV and DMAV) on the expression of 
genes for NEFH, NEF3, NEFL and MAPT in two different cell lines originating respectively 
from the peripheral (ST-8814) and central (SK-N-SH) nervous system.  
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2. Materials and Methods 
 
Chemicals. The following arsenic metabolites and chemicals were purchased from Sigma-
Aldrich (St. Louis, MO, USA): (catalogue no.: PS-281), Sodium meta-arsenite (AsIII) (product 
no. 228699-100G), Arsenic acid sodium (AsV) (product ref. A6756-50G), Trypsin-EDTA 
solution 1x (catalogue no. T3924), and retinoic acid 98% (all-trans C20H28O2, Vitamin A, 
product no.: R2625). Dimethyl arsenic acid (DMAV) (catalogue no.: PS-51) and Disodium 
methyl arsenate (MMAV) were obtained from Chem Service (West Chester, USA). 
AlamarBlue dye was purchased from BioSource International, Inc. (catalogue no.: DAL1100. 
Camarillo, CA). RNeasy Mini Kit 250 was purchased from Qiagen Inc (catalogue no.74106, 
Valencia, CA, USA). Deoxyribonucleotide triphosphate (dNTPs) 5 mM, 0.1 M dithiothreitol 
(DTT), 5x buffers, reverse transcriptase (RT) and RNA inhibitor 40 units/µl (RNA sin) were 
purchased from Promega (Benelux BV, Netherlands). T-25 flasks with air-filter cap for cell 
growth were obtained from Greiner bio-one GmbH (catalogue no. 690175. Frickenhausen, 
Germany). Mouse anti-NF-90 antibody to all three neurofilament proteins (NF-H, NF-M and 
NF-L) was a gift from Prof. E. Marani of the Department of Neurosurgery at the Leiden 
University Medical Center, Netherlands (Oudega et al., 1996). Mouse anti-tau monoclonal antibody, 
Clone Tau 46 (catalog no. Ab24747) was obtained from Abcam (Cambridge, United Kingdom). 
Kodak Biomax XAR film (catalog no. 165 1454) was obtained from Kodak (Shelton, CT, 
USA). ECL plusTM western blotting detection reagent was bought from Amersham 
Biosciences (Piscataway, NJ, USA).  
 SYBRGreen PCR-mastermix 2x (P/N: 4309155, Foster City, CA, USA) was purchased from 
Applied Biosystems. Phosphate-buffered saline (PBS, NaCl 145 mmol/l, phosphate 1.4 
mmol/l and pH 7.5) was prepared from analytical grade reagents by the Department of 
Pharmacy. The used primers were all obtained from Isogen Bioscience B.V (IJsselstein, the 
Netherlands) (Table 1) with an end concentration of 10pmol/µl in Tris/EDTA-buffer. 
Cell cultures. Most of the materials for cell culture were purchased from Invitrogen (Breda, 
the Netherlands); otherwise more specific details are followed in brackets. A human 
neuroblastoma cell line and SK-N-SH cells were purchased from the American Type Culture 
Collection. The SK-N-SH cell line was maintained in Advanced Minimum Essential Medium 
(Advanced MEM) (catalogue no. 12492-013) supplemented with 10% heat-inactivated foetal 
bovine serum obtained from Greiner bio-one GmbH (catalogue no. 758093) (Frickenhausen, 
Germany), 2% sodium bicarbonate (catalogue no. 25080-094), 1 % L-glutamine (catalogue 
no. 25030-081) and 100 µg/ml penicillin/streptomycin (catalogue no. 15140-122) at 37˚C in a 
5% CO2 incubator. The Schwannoma cell line ST-8814 cell line was established from 
malignant schwannomas (neurofibrosacromas) from patients with neurofibromatosis type 1 
(Ryan et al., 1994). The ST-8814 was maintained in Iscove’s Modified Dulbecco’s Media 
(IMDM) (Cambrex, catalogue no. BE12-722F), supplemented with 10% heat-inactivated 
foetal bovine serum obtained from Greiner bio-one GmbH (catalogue no. 758093) 
(Frickenhausen, Germany), 100 µg/ml penicillin/streptomycin (catalogue no. 15140-122) at 
37˚C in a 5% CO2 incubator. 
Cytoskeletal protein expression. The three neurofilament proteins (NF’s) and MAP-tau 
expression were analyzed by using the western blot technique. Both cell lines were grown in 
T-25 flasks. After trypsinization, the cells were centrifuged at 350xg and washed twice with 
PBS for 10 minutes at 4ºC. Afterwards, the cells were collected in 100µl of PBS and lysed by 
freeze-thawing procedure in liquid nitrogen (-80ºC) and water bath (37ºC), 3 times for 3 
minutes each. The lysed cells were centrifuged at 10000xg for 1 min at room temperature and 
the supernatant was transferred in to a new 1.5ml tube. Protein concentrations of the 
homogenates were measured by the BCATM Protein Assay Kit. To obtain the same protein 
concentrations prior to analysis by SDS-PAGE, the protein samples were standardized with 
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PBS. The protein samples were analyzed on an 8% acrylamide separation gel (Laemmli, 
1970). The separation gels were used for immunoblotting on 0.2 µm nitrocellulose 
membranes in conjunction with monoclonal neurofilament antibodies to all 3 neurofilament 
proteins: NF-H, NF-M, NF-L, and MAP-tau. Using ECL plusTM western blotting detection 
reagent and exposing to Kodak Biomax XAR film for 30 seconds to 3 minutes concluded the 
western blot analysis. The band intensities on the Kodak biomax XAR film were analyzed by 
Quantity One – Densitometer GS-710 from Bio-Rad (Veenendaal, The Netherlands). 
Experimental design. Cells were cultivated in triplicate for each As metabolite and 
concentration. From each culture, PCR was performed in duplicate, so each PCR was 
performed six times in total. First the growth rate of the cell lines ST-8814 and SK-N-SH and 
the effect of arsenic metabolites iAsIII, iAsV, MMAV and DMAV on the growth rate were 
determined to provide a measure for the sensitivity of the cells and to give an overall picture 
of the toxicity of these metabolites. 
The growth rates of the cell lines were determined by using the AlamarBlue assay to establish 
the growth rate and cytotoxicity of arsenic metabolites (Fields et al., 1993). The AlamarBlue 
assay incorporates a fluorometric/colorimetric growth indicator based on detection of 
metabolic activity. This assay incorporates an oxidation-reduction indicator that both 
fluoresces and changes color in response to the chemical reduction of growth medium 
resulting from cell growth (Page et al., 1993). The linearity of this assay (cell titration) was 
tested by making a trend line of both cell lines in a 24-wells plate and incubated overnight at 
37˚C in a 5% CO2 incubator. The used cell amounts were 0, 20, 40, 60, 80 and 100 (x1000) 
cells per well in triplicate. Subsequently, the cells were washed with phosphate-buffered 
saline (PBS), and medium containing 10% AlamarBlue dye was then added to the cells and 
incubated at 37˚C in a 5 % CO2 incubator. Samples were taken after 24 hours. The absorbance 
of the cells was then measured in a 96-wells plate with the SpectraMAX 250 Micro plate 
Spectrophotometer from Molecular Devices (Wokingham, UK) at 540/630 nm (Fig. 2A). Use 
of AlamarBlue each time for the same duration of 24 hrs, provides the means to calculate the 
number of cells present in a well in conjunction with the trendline equation shown in Fig 2A. 
The concentration that kills 50% of the cells in culture (LC50) was also measured for each 
metabolite by using AlamarBlue dye. AlamarBlue dye was used as an indicator for the 
number of cells that survived in comparison to the controls, and as a means to standardize the 
used concentrations for both cell lines. The same amount of cells - 2x104 - was added in 1 ml 
medium into each well on a 24-wells plate and incubated for 24-hours at 37˚C in a 5% CO2 
incubator. After 24-hours the cells were treated with various concentrations (0, 1, 3, 10 and 30 
µM) of the arsenic compounds iAsIII, iAsV, MMAV and DMAV, and incubated for another 24-
hours at 37˚C in a 5% CO2 incubator.  
Subsequently, the cells were washed with PBS, and medium containing 10% AlamarBlue dye 
was then added to the cells and incubated for 24-hours at 37˚C in a 5 % CO2 incubator. The 
absorbance of the cells was then measured in a 96-wells plate with the SpectraMAX 250 
Microplate Spectrophotometer at 540/630 nm, where LC50 values were calculated by. The 
LC50 assay was performed in triplicate (Fig. 3A and B). 
For the actual gene expression experiment, 1.106 cells were grown per Tissue Culture Flasks 
(T25) 25cm2, from Greiner bio-one GmbH (catalogue no. 690 175) (Frickenhausen, 
Germany). Various As metabolites (iAsIII, iAsV, MMAV and DMAV) and concentrations of 0, 
0.3, 1.0 and 3.0 µM dissolved in their appropriate cell culture medium were incubated for 24- 
and 48-hours. Afterwards, cells in T25 flasks were washed twice with PBS and RNA was 
isolated and purified from the cells by using Qiagen RNeasy mini columns (for more details, 
see RNeasy mini protocol for isolation of total RNA from animal cells). Ultimately cDNAs 
with an end concentration of 25 ng/µl were synthesized from the isolated RNAs and the 
samples were analyzed with the Applied Biosystems 7300/7500 Real Time PCR System 
Arsenic Neurotoxicity III 
 71 
(Nieuwerkerek a/d Ijssel, the Netherlands). The used software, Relative Quantification (RQ), 
determines the change in expression of a nucleic acid sequence (target) in a test sample 
relative to the same sequence in a calibrator sample, after all the measurements are 
standardized through a chosen household gene (Livak and Schmittgen et al., 2001). The 
relative expression of each gene for the various doses and time indices are compared to their 
control groups for each time indices and 0 µM. 
The data for each gene were statistically evaluated for each dose and time using the SPSS 
14.0 for Windows. The t-Test for independent samples was used to evaluate the data for a 
single gene in both cell cultures (Fig. 1B). Chi-Squared for non-parametric tests (Kruskal-
Wallis test) was performed to evaluate the data for dose and time and As metabolites as 
obtained for each gene. A level of p<0.05 was accepted as statistically significant. 
 
 
Table 1. Primer sequences used for the various cytoskeletal genes. 
    
Name     Sequence (5’-->3’)    Gene 
 
ß2-Microglobuline-Sense   GATGCTGCTTACATGTCTCG   Household 
ß2-Microglobuline-Anti-sense  CCAGCAGAGAATGGAAAGTC   Household 
MAPT-Sense    TCACTTTTACAGCAACAGTCAGTG  Target 
MAPT-Anti-sense    TGCCATGTTGAGCAGGACTA   Target 
NEFH-Sense    GCCGAATGCCACACGTAAACACTT  Target 
NEFH-Anti-sense    AAAGTGCGCCCTGGCATAATTCAG  Target 
NEF3-Sense    AGAATATGCACCAGGCCGAAGAGT  Target  
NEF3-Anti-sense    GCAAATGACGAGCCATTTCCCACT  Target 
NEFL-Sense    AAGCATAACCAGTGGCTACTCCCA  Target 
NEFL-Anti-sense    TCCTTGGCAGCTTCTTCCTCTTCA  Target 
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3. Results 
 
The presence of the cytoskeletal intermediate filament proteins in the used cell lines is shown 
in Fig.1A. MAP-tau, NF-H, NF-M and NF-L are present in both SK-N-SH and ST-8814 cell 
lines. Fig 1A and 1B compares the neurofilament expression on the protein and mRNA levels 
in both cell lines. The SK-N-SH cell line shows a higher RNA expression for MAPT and 
NEFL by 3 to 4 fold (t-Test, p<0.05) (Fig. 1B). The expression levels of NEFH and NEF3 in 
both cell lines are similar. 
 
  
1A.      1B. 
 
Fig. 1. 1A and 1B show the comparison of the different cytoskeletal protein and their gene expressions of 
various NFs and MAP-tau proteins in the SK-N-SH and ST-8814 cell lines. The t-Test for independent samples 
for each measured value per gene group revealed significant between-group differences as follows: MAPT and 
NEFL p<0.05 and no significant difference between the NEFH and the NEF3 of both cell lines. Fig 1B shows 
the relative mean values (± SD; n=6). 
 
Both cell cultures were studied in conjunction with AlamarBlue dye to establish their cell 
amounts versus their proportional absorption levels (Fig. 2A). As can be seen from Fig. 2A, 
the ST-8814 cells have higher absorption for the same number of cells in comparison to SK-
N-SH cells, namely 0.68 and 0.95 units for 2x104 and 1x105 ST-8814 cells respectively, in 
comparison to 0.57 and 0.71 units for 2x104 and 1x105 SK-N-SH cells.  The growth rates of 
both cell lines were determined during 72 hours, using AlamarBlue dye as a measuring tool 
for the number of cells present at a certain time (Fig. 2.B).  
 
  
 
Fig. 2A. Linearity measurements (cell titration) of ST-8814 (R2 = 0.8422) and SK-NSH (R2 = 0.887) cell lines 
with AlamarBlue. These trend lines of indicate that the higher the amount of cells the greater the absorbance. 
The overall measured absorbances of the ST-8814 cells are higher than those of the SK-N-SH cells. 
Fig. 2B. The growth rates of the two cell lines were measured during 72 hours. Mean values ± SD, n=3. 
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The LC50 for each cell line and for each As metabolite was determined by using AlamarBlue 
dye. Both ST-8814 and SK-N-SH responded differently to As metabolites, except for iAsIII 
(Fig. 3A and 3B). In both cultures, iAsIII was most lethal (Chi square test, p<0.05). The LC50 
for ST-8814 is 12.82 µM and for SK-N-SH 17.63 µM.  
 
  
3A. ST8814              3B. SK-N-SH 
Fig. 3. LC50 measurements of various arsenic metabolites. Absorbance of A. ST-8814 and B. SK-N-SH cells 
after treatment with 0, 1, 3, 10 and 30 µM of the arsenic metabolites AsIII, AsV, MMAV and DMAV. In both cell 
lines AsIII is the most toxic form (P<0.05). From these trend lines, the LC50 for the four arsenic metabolites per 
cell line was calculated. Mean value;  n=3. 
 
 
The performed RT-PCR on both cell cultures was carried out by using the following 
concentration series; 0, 0.3, 1.0 and 3.0 µM of each arsenic compound, well below the LC50 of 
both cell lines. For the RT-PCR, relative quantification was used as a measure for the changes 
in expressions of the nucleic acid sequences of the targets (MAPT, NEFH, NEF3 and NEFL), 
relative to the same sequence in a standard, namely ß2-Microglobuline household gene (see 
table 1). 
 
3.1. Effects of As on the gene expression of cytoskeletal proteins in Schwannoma cell 
line, ST-8814. 
 
3.1.1. Effects of inorganic trivalent arsenic (iAs
III
) in ST-8814 (Fig. 4A).   
MAPT shows an increase after 24 hours for all 3 doses (p<0.05), and there were no significant 
changes after 48 hours. NEFH, NEF3 and NEFL show no significant changes after 24 or 48 
hours.  
3.1.2. Effects of inorganic pentavalent arsenic (iAs
V
) in ST-8814 (Fig. 4B).   
There are no significant changes on any of the MAPT, NEFH, NEF3 and NEFL genes after 
24 or 48 hours. 
3.1.3. Effects of organic monomethyl pentavalent arsenic (MMA
V
) in ST-8814 (Fig. 4C).   
MAPT shows no significant changes for all 3 doses after 24 or 48 hours. NEFH increases in 
the first 24-hours at all 3 concentrations, almost fourfold at 0.3 µM and twofold at 1.0 and 3.0 
µM (p<0.05).  After 48 hours, the increase is not as high as in the first 24 hours for the 0.3 
µM, and it remains unchanged for the 1.0 and 3.0 µM during the second day (p<0.05). NEF3 
has the most significant increase, especially at the 1.0 µM dose after 24 hours (p<0.05), but 
after 48-hours all the doses result in a lower expression level in comparison to their control. 
NEFL shows no significant changes after 24 or 48 hours.  
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3.1.4. Effects of organic dimethyl pentavalent arsenic (DMA
V
) in ST-8814 (Fig. 4D).   
MAPT shows no significant changes for the 3 doses after 24 or 48 hours. NEFH shows almost 
the same expression pattern with DMAV as with MMAV; an increase both after 24 and 48 
hours (p<0.05), although the increase after 48 hours is slightly lower than the first 24 hours. 
NEF3 also shows a similar expression pattern for DMAV as in MMAV, a significant increase 
after 24 hours (p<0.05) and leveling off to the control level after 48 hours. NEFL shows a 
significant increase in the first 24 hours (p<0.05) and leveling off to the control level after 48 
hours.  
 
  
4A.      4B. 
 
  
4C.      4D. 
 
Fig. 4. Effects of various arsenic metabolites and concentrations on the various cytoskeletal gene expressions of 
Schwannoma cell line ST-8814 (*, p<0.05). Relative mean values ± SD; n=6.  
 
 
3.2. Effects of As on the gene expression of cytoskeletal proteins in neuroblastoma cell 
line, SK-N-SH. 
 
3.2.1. Effects of inorganic trivalent arsenic (iAs
III
) in SK-N-SH (Fig. 5A).  
MAPT shows no significant changes for the 3 doses after 24 or 48 hours. NEFH is unchanged 
after 24 hours. The expression levels for NEFH is increased after 48 hours for all three 
concentrations (p<0.05). NEF3 and NEFL are unchanged for the 3 doses after 24 or 48 hours. 
3.2.2. Effects of inorganic pentavalent arsenic (iAs
V
) in SK-N-SH (Fig. 5B).  
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There are no significant changes on any of the MAPT, NEFH, NEF3 and NEFL genes after 
24 or 48 hours. 
3.2.3. Effects of organic monomethyl pentavalent arsenic (MMA
V
) in SK-N-SH (Fig. 
5C).  
MMAV shows the most profound effects on the cytoskeletal genes. MAPT expression is not 
significantly changed after 24 hours, but it is significantly increased after 48 hours (p<0.05). 
NEFH expression increased significantly for all three concentrations after 24 and 48 hours 
(p<0.05). NEF3 and NEFL have a similar expression pattern to its MAPT with no significant 
changes after 24 hours but they are increased after 48 hours (p<0.05).  
3.2.4. Effects of organic dimethyl pentavalent arsenic (DMA
V
) in SK-N-SH (Fig. 5D).  
MAPT shows no significant changes for the 3 doses after 24 or 48 hours. NEFH is 
significantly increased after 24 and 48 hours (p<0.05). NEF3 and NEFL are unchanged for all 
3 doses after 24 or 48 hours. 
 
  
5A.      5B. 
 
  
5C.      5D. 
 
Fig. 5. Effects of various arsenic metabolites and concentrations on the various cytoskeletal gene expressions of 
Neuroblastoma cell line SK-N-SH (*, p<0.05). Relative mean values ± SD; n=6. 
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4. Discussion 
 
The used cell lines were first characterized for the presence and comparison of the different 
cytoskeletal proteins and their gene expressions of various NFs and MAP-tau proteins in the 
SK-N-SH and ST-8814 cell lines (Fig. 1A and B). On this basis, we compare these cell lines 
and considered them to be representative for the CNS (SK-N-SH) and the PNS (ST-8814). 
SK-N-SH (neuroblastoma) cells are derived from the CNS; ST-8814 cells are cultivated from 
Schwannoma cells, which are derived from the PNS. 
In most mammalian species As is metabolized from inorganic As to methylarsonic acid 
(MMA) and dimethylarsinic (DMA) by alternating reduction of pentavalent arsenic to 
trivalent and addition of a methyl group. This biotransformation of inorganic to organic 
arsenic is considered to be a detoxification step, due to the fact that methylated arsenics are 
reportedly less cytotoxic (Vahter and Concha, 2001). This is confirmed in this study as well 
by the effects of iAs on the LC50 of the studied cell lines (Fig. 3). This study was, however, 
also designed to clarify the effects of As-metabolites on the genes encoding for the 
cytoskeletal proteins NFs and MAPT.  Both cell lines show linear properties (cell titration) for 
the increasing number of cells (Fig. 2A), with the difference that ST-8814 cells have higher 
absorption for the same number of cells in comparison to the SK-N-SH cells. This higher ratio 
is achieved by the higher slope coefficient of 0.0030 in ST-8814 than the slope coefficient of 
0.0019 in SK-N-SH cells (Fig. 2A) in conjunction with their growth rate (Fig. 2B). This 
higher ratio shows that the ST-8814 cells have much higher redox reactions.  The difference 
in absorption for blank wells (background) is caused by the use of two different cell culture 
mediums. ST-8814 has a doubling time of 20.44 hrs and SK-N SH has a doubling time of 
17.74 hrs. The doubling time (growth rate) of the cells was calculated by using the absorption 
levels of each cell between 80 and 40 x1000 cells in Fig 2A, and subsequently using the curve 
equations of each cell (Fig. 2B) to calculate the doubling time. 
AlamarBlue dye was also used to determine the LC50 of various arsenic metabolites for both 
cell lines (Fig. 2).  As expected, iAsIII turns out to be the most lethal metabolite for both cell 
lines. Microscopic observations showed that at the highest concentration levels (30 µM), 
complete lethality was achieved. The LC50 for iAs
V, MMAV and DMAV could not be 
calculated in both cell lines. At the highest concentration levels (30 µM) of these three 
metabolites, complete lethality was not achieved. 
Neurofilament and microtubule-associated protein-tau disorganization is a mark of various 
diseases (Pant et al., 1995). Tau regulates microtubule assembly, and stability is also involved 
in the establishment and maintenance of neuronal polarity. Dubois et al. (2005) concluded that 
NF-L protein plays an essential part in motor function, since mice with the deleted NEFL 
gene showed impaired motor functions (Dubois et al., 2005). In our previous work we showed 
that single exposure to iAsIII (i.v.) in rats cause changes in axonal cytoskeletal protein 
composition, namely that NF-L diminishes dependent on the dose and exposure time 
(Vahidnia et al., 2006). NF-L protein seems to play the most important role in neurofilament 
assembly in a number of neurodegenerative diseases, since it is the only neurofilament protein 
capable of organizing filaments on its own (Carpenter et al., 1996). 
In agreement with this view, we show here that expression of the NEFL gene changes by 
DMAV in the ST-8814 cell line and MMAV in the SK-N-SH cell line. Furthermore, NEF3 and 
MAPT genes show to some extent the same expression patterns as NEFL gene under the 
influence of various As metabolites. However, NEFH expression is in the majority of the 
observations increased for both MMAV and DMAV metabolites in both cell lines (Fig. 4 and 
5). A decrease in mRNA expression may also result in decrease in its translation to the 
corresponding protein. These findings suggest that in order to keep their cytoskeletal integrity, 
both cell types compensate the decrease in MAPT, NEF3 and NEFL by a significant increase 
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in NEFH (Fig. 4C, 4D, 5C and 5D). This explanation is supported by the fact that iAsIII and 
iAsV metabolites do not cause an overall significant increase or decrease in the expression of 
MAPT, NEF3 and NEFL genes (Fig. 4A, 4B, 5A and 5B) and, as a result, there is no 
significant increase of NEFH evident in cells incubated with iAsIII and iAsV. 
Studies performed by Breen and Anderton (1991) in NEURO-3A neuroblastoma cells reveal 
that mRNA expression of NEFL and NEF3 are co-regulated while the NEFH gene is 
expressed independently. NEFL and NEF3 are expressed days before the appearance of 
NEFH (Breen and Anderton, 1991).  Our results on NEFL and NEF3 expression are in 
agreement with their findings. In both cell lines, NEFL and NEF3 expressions are co-
regulated, especially when MMAV and DMAV metabolites are used (Fig. 4C, 4D, 5C and 5D). 
The expression of these two genes could be co-regulated since both genes can be found on the 
same chromosome, namely: 8p21. At the same time, NEFH with the same arsenic metabolites 
does not follow the same expression pattern. NEFH increases in both cell lines and with both 
MMAV and DMAV metabolites. Furthermore, although MAPT in our study shows no 
significant changes, its expression pattern is similar to as expression patterns in NEF3 and 
NEFL. This may suggest that MAPT expression could also be co-regulated with the 
expression of NEFL and NEF3. An obvious explanation for the probable co-regulation of 
NEFL and NEF3 on the one hand, and MAPT on the other, is not readily available, as the 
MAPT gene is located on chromosome 17q21.1. 
In conclusion, it can be said that although iAsIII and iAsV metabolites are more lethal for both 
cell lines, the MMAV and DMAV metabolites are more toxic to the genes regulating the 
neurofilament proteins under study. MMAV and DMAV metabolites show large variations in 
expression of the cytoskeletal genes. Although iAsIII is most lethal but not genotoxic, it 
contributes to (hyper) phosphorylation of neurofilament and tau proteins (Giasson et al.,  
2002; Shea et al., 2003). Phosphorylation of neurofilament proteins change cytoskeletal 
protein composition, phosphorylated or hyperphosphorylated neurofilament proteins tend to 
accumulate in the cell body in vivo (Shea et al., 2003). The same is also true for arsenite 
induced hyperphosphorylated tau proteins (Giasson et al., 2002). As a result, 
hyperphosphorylated tau proteins are not able to organize microtubules in cells. The altered 
cytoskeletal gene expressions combined with the hyperphosphorylation of cytoskeletal 
proteins gives insight into the effects and neurotoxic mechanism of various arsenic 
metabolites.  
In this study, we have been able to demonstrate altered cytoskeletal gene expression by 
various arsenic compounds. The significant increase of NEFH and simultaneous change of 
NEFL, NEF3 and MAPT may lead to changes in cytoskeletal composition, which in turn can 
influence axonal transport and result in diminished nerve conduction velocity (Le Quesne et 
al., 1977; Lagerkvist et al., 1994). This is in agreement with the observation that As 
intoxication may cause neuropathy (Hafeman et al., 2005). 
In a next study in preparation, we will describe how changes in the cytoskeletal proteins may 
occur as a result of exposure to As metabolites. 
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Abstract 
 
In recent studies we have demonstrated that arsenic (As) metabolites change the composition 
of neuronal cytoskeletal proteins in vivo and in vitro. To further examine the mechanism of 
arsenic-induced neurotoxicity with various arsenate metabolites (iAsV, MMAV and DMAV) 
and arsenite metabolites (iAsIII, MMAIII and DMAIII) we investigated the role of the 
proteolytic enzyme calpain and its involvement in the cleavage of p35 protein to p25, and also 
mRNA expression levels of calpain, cyclin-dependant kinase 5 (cdk5) and glycogen synthase 
kinase 3 beta (gsk3ß). A HeLa cell line transfected with a p35 construct (HeLa-p35) was used 
as a model, since all other proteins such as calpain, CDK5 and GSK3ß are already present in 
HeLa cells as they are in neuronal cells. HeLa-p35 cells were incubated with various As 
metabolites and concentrations of 0, 10 and 30 µM for duration of 4 hours. Subsequently the 
cells were either lysed to study their relative quantification levels of these genes or to be 
examined on their p35-protein expression. P35-RNA expression levels were significantly 
(p<0.01) increased by arsenite metabolites, while p35 protein was cleaved to p25 (and p10) 
after incubation with these metabolites. The cleavage of p35 is caused by calcium (Ca2+) 
induced activation of calpain. Inhibition of calpain activity by calpeptin prevents cleavage of 
p35 to p25. These results suggest that cleavage of p35 to p25 by calpain, probably As-induced 
Ca2+-influx may explain the mechanism by which arsenic induces its neurotoxic effects.  
 
Keywords: Arsenate and arsenite metabolites; Calpain; HeLa cells; Neurotoxicity; p35. 
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1. Introduction 
Long-term exposure to As causes serious effects to various organs such as bladder, kidney, 
liver, lung and skin cancer, cardiovascular disease and neurological effects.  
Neurological effects of As may develop within a few hours after ingestion but are usually 
seen 2-8 weeks after exposure (Kishi et al. 2001; Jha et al. 2002). It is usually a symmetrical 
sensori-motor polyneuropathy, often resembling Guillain-Barré syndrome (Perriol et al. 
2006).  The predominant clinical features of neuropathy are paresthesias, numbness, and pain, 
particularly of the soles of the feet. Electrophysiological studies performed on patients with 
As neuropathy have revealed a reduced nerve conducting velocity (NCV), typical of those 
seen in axonal degeneration, which was confirmed by sural nerve biopsy (Hilmy et al. 1991). 
However, the mechanism of action of As-induced neurotoxicity is poorly understood.  
Neurological disorders have been correlated with disorganization and changes in the 
expression levels of neuronal cytoskeleton proteins such as neurofilament-high (NF-H), 
neurofilament-middle (NF-M), neurofilament Low (NF-L) and microtubule associated protein 
tau (MAP-tau) (Trojanowski et al. 1993). 
In specific neurodegenerative diseases such as Alzheimer’s Disease (AD), the accumulation 
of amyloid beta peptide is believed to be an early and critical event leading to synapse and 
neuronal cell loss (Smith et al., 2006). Subsequently,  neurofibrillary tangles are formed by 
tau hyperphosphorylation (Alonso et al. 1996). This hyperphosphorylation is caused by 
proteolytic cleavage of p35 to p25 by calpain at a specific site post-translationally, whereby 
p25 acts as hyperactivator of CDK5. P35 and also p25 are the neuron specific activator of 
CDK5. CDK5 is involved in terminal differentiation of neurons and muscle cells. The 
p35/CDK5 protein complex is required for proper development of the central nervous system 
and is this complex is required for neurite outgrowth (Nikolic et al. 1996).  Calpain is a Ca2+ 
dependant kinase enzyme, which is activated by the internal increase of Ca2+ in the cells. 
Activated calpain is responsible for the cleavage of p35 to p25 (Lee et al. 2000). 
Hyperphosphorylation of cytoskeletal proteins is a potential mechanism of neurodegenerative 
disease, which is result of p25 overexpression, such as in AD-patients (Monaco 2004; 
Ahlijanian et al. 2000). A p25-mediated increase in CDK5 activity results in 
hyperphosphorylation of tau and neurofilaments (NFs). As a result microtubule (MT) network 
will destabilize leading to disruption of cytoskeleton (Trojanowski et al. 1993; Alonso et al. 
1996). Glycogen synthase kinase 3 is involved in energy metabolism, neuronal cell 
development, and body pattern formation. GSK3ß also regulates the microtubule cytoskeleton 
during axon outgrowth (Goold & Gordon-Weeks 2001).  
In our previous studies, we have shown that iAsIII causes compositional changes in sciatic 
nerve proteins, namely reduction in NF-L expression (Vahidnia et al. 2006). Furthermore, in 
vitro studies with various arsenic metabolites have shown that MMAV and DMAV affect 
expression of neurofilaments and tau genes, but not iAsIII (Vahidnia et al. 2007). 
Neurofilament-L decrease may play an important role in the pathological changes of nervous 
system, since NF-L is the only NF protein capable of organizing and co-assembling of 
filaments on its own in vivo. Both NF-H and NF-M need a NF-L protein to form a 
heteropolymer in the cytoskeletal framework (Carpenter & Ip 1996). Arsenite is also known 
to phosphorylate tau proteins (Giasson et al. 2002) and we have also seen similar results in 
sciatic nerves of rats exposed to iAsIII, whereby tau proteins were hyperphosphorylated (as yet 
unpublished). Hyperphosphorylated tau proteins have a reduced ability to bind to 
microtubules. Decrease in NF-L and hyperphosphorylation of tau proteins under As-induced 
toxicity.  
Here we investigated a possible mechanism of As-induced neurotoxicity by which arsenite 
metabolites may be responsible for hyperphosphorylation and degradation of NF and tau 
proteins caused by cleavage of p35 to the p25 fragment. Transfected HeLa-p35 cells were 
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incubated with various As metabolites. Gene expression levels were monitored for p35, 
calpain, CDK5 and GSK3ß. Furthemore, the cleavage of p35 to p25 after incubation with 
arsenite metabolites was studied by western blot experiments.  
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2. Materials 
 
2.1. Chemicals.  
 
The following arsenic metabolites and chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO, USA): (catalogue no.: PS-281), Sodium meta-arsenite (AsIII) (product no. 
228699-100G), Arsenic acid sodium (AsV) (product ref. A6756-50G), Trypsin-EDTA 
solution 1x (catalogue no. T3924). Dimethyl arsenic acid (DMAV) (catalogue no. PS-51) and 
Disodium methyl arsenate (MMAV) were obtained from Chem Service (West Chester, USA). 
Methylarsonous diiodide (MMAIII) and Dimethylarsinous iodide (DMAIII) were purchased 
from Dr. Cullen of the Department of Chemistry at the University of British Columbia, 
Vancouver, Canada. AlamarBlue dye was purchased from BioSource International, Inc. 
(catalogue no. DAL1100. Camarillo, CA). RNeasy Mini Kit 250 was supplied by Qiagen Inc 
(catalogue no.74106, Valencia, CA, USA). Deoxyribonucleotide triphosphate (dNTPs) 5 mM, 
0.1 M dithiothreitol (DTT), 5x buffers, reverse transcriptase (RT) and RNA inhibitor 40 
units/µl (RNA sin) were purchased from Promega (Benelux BV, Netherlands). T-25 flasks 
with air-filter cap for cell growth were obtained from Greiner bio-one GmbH (catalogue no. 
690175. Frickenhausen, Germany).  Monoclonal antibody to GAPDH (catalog no. Ab8245) 
and rabbit polyclonal anti-p35 (catalog no. Ab10570) were supplied by Abcam (Cambridge, 
United Kingdom). Rabbit polyclonal anti-Calpain (H-60) (catalog no. sc-30065), goat anti-
rabbit IgG-HRP (catalog no. sc-2004) and goat anti-mouse IgG-HRP (catalog no. sc-2055) 
were purchased from Santa Cruz biotechnology, Inc. (Califorina, USA). Cyclin-dependant 
kinase 5, regulatory subunit 1 (CDK5R1, p35) construct (catalog no. IOH11747-pDEST26) 
was purchased from RZPD (Berlin, Germany) and LipofectamineTM 2000 (catalog no. 11668-
019) from Invitrogen (Breda, The Netherlands). Calpeptin (catalog no. 03-34-0051) was 
purchased from Calbiochem (Darmstadt, Germany). Kodak Biomax XAR film (catalog no. 
165 1454) was obtained from Kodak (Shelton, CT, USA). ECL plusTM western blotting 
detection reagent was bought from Amersham Biosciences (Piscataway, NJ, USA). 
SYBRGreen PCR-mastermix 2x (P/N: 4309155, Foster City, CA, USA) was purchased from 
Applied Biosystems. Phosphate-buffered saline (PBS, NaCl 145 mmol/l, phosphate 1.4 
mmol/l and pH 7.5) was prepared from analytical grade reagents by the Department of 
Pharmacy. The used primers were all obtained from Isogen Bioscience B.V (IJsselstein, the 
Netherlands) with a final concentration of 10 pmol/µl in Tris/EDTA-buffer (Table 1).  
 
Table 1. Primer sequences used for the RT-PCR. 
 
Name     Sequence (5’-->3’)    Gene 
 
ß2-Microglobuline-Sense   GATGCTGCTTACATGTCTCG   Household 
ß2-Microglobuline-Anti-sense  CCAGCAGAGAATGGAAAGTC   Household 
Cdk5-Sense    GCACAAGAACATCGTCAGGCTTCA  Target 
Cdk5-Anti-sense    GTGTAGCACATTGCGGCTATGACA  Target 
Gsk3β-Sense    TGATTCAGGAGAACTGGTCGCCAT  Target 
Gsk3β-Anti-sense    TTTCCGGAACATAGTCCAGCACCA  Target 
µ-Calpain-Sense    ACGAGAACTTCAAGGCCCTCTTCA  Target 
µ-Calpain-Anti-sense   TGCCATCACGATCCATGAGGTTCA  Target 
m-Calpain-Sense    ACCGAGAAATCGACGTTGACAGGT  Target  
m-Calpain-Anti-sense   CAGCCGAACCAAACACCGAACAAA  Target 
p35-Sense    TGACATGCCTGTACCTCTCCTACT  Target 
p35-Anti-sense    CGGAGAAGACCTGTGTGAAGTAGTGT  Target 
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2.2 Cell cultures.  
 
Most of the materials for cell culture were purchased from Invitrogen (Breda, The 
Netherlands); otherwise more specific details are followed in brackets. HeLa cells were grown 
in Dulbecco’s modified Eagle’s medium (DMEM, catalog no. ) and were supplemented with 
10% heat-inactivated foetal bovine serum obtained from Greiner bio-one GmbH (catalogue 
no. 758093) (Frickenhausen, Germany) and supplemented with 100 IU/ml 
penicillin/streptomycin (catalogue no. 15140-122), and maintained at 37 °C, 5% CO2 in a 
humidified incubator. 
 
2.3. Cell Transfection. 
 
HeLa cells were seeded in T25 flasks for a transient transfection and grown to 70-80% 
confluence for 24 h. HeLa cells were exposed to a mixture of 30 µl of Lipofectamine 
ReagentTM (Invitrogen) and 8 µg of plasmid DNA for 5 h in serum-free medium, after which 
the medium was refreshed by a full culture medium. After 24 h, the transfected cells were 
trypsinized and seeded in a 6-wells plate and grown to a 80-90% confluence, ready for 
treatment. 
 
2.4. Protein expression.  
 
Calpain, CDK5, GAPDH, GSK3β and p35 expression was analyzed by the western blot 
technique in triplicate. Transfected HeLa cells were grown in 6-wells plates. After 
trypsinization, the cells were centrifuged at 350xg and washed twice with PBS for 6 minutes 
at 4ºC. Afterwards, the cells were collected in 100µl of lysis buffer containing 25mM Tris-
base, 2.5% SDS (w/v) and 2.5 mM DTT at pH 6.8. After addition of lysis buffer, cells were 
incubated at 100ºC for 5 minutes before and after lysing by freeze-thawing in liquid nitrogen 
(-80ºC) and a water bath (37ºC), 3 to 4 times for 3 minutes each. Protein concentrations of the 
homogenates were measured by the BCATM Protein Assay Kit. To obtain the same protein 
concentrations prior to analysis by SDS-PAGE, the protein samples were standardized with 
lysis buffer. The protein samples were analyzed on an 8 or 12% acrylamide separation gel. 
The western blot analysis of the same samples was performed in triplicate. 
 
2.5. Experimental design.  
 
2.5.1. Relative Quantification of various genes. 
 
For RT-PCR, cells were cultivated in triplicate for each As metabolite and concentration. 
From each culture, PCR was performed in duplicate, so each PCR was performed six times in 
total (n=6). For the study of gene expressions, cells were grown in 6-wells plates, from 
Corning Incorporated Costar (catalogue no. 3506) (Frickenhausen, Germany) till 80-90% 
confluency was reached. Various As metabolites (iAsIII, iAsV, MMAIII, MMAV, DMAIII and 
DMAV) in concentrations of 0, 10 and 30 µM dissolved in cell culture medium were 
incubated for 4-hours. Afterwards, cells in 6-wells plate were washed twice with PBS and 
RNA was isolated and purified from the cells by using Qiagen RNeasy mini columns (for 
more details, see RNeasy mini protocol for isolation of total RNA from animal cells). 
Ultimately cDNAs with a final concentration of 20 ng/µl were synthesized from the isolated 
RNAs and the samples were analyzed with the Applied Biosystems 7300/7500 Real Time 
PCR System (Nieuwerkerk a/d IJssel, the Netherlands). The used software, Relative 
Quantification (RQ), determines the change in expression of a nucleic acid sequence (target) 
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in a test sample relative to the same sequence in a calibrator sample, after all the 
measurements are standardized through a chosen household gene (Livak et al. 2001). The 
relative expressions of each gene for the various concentrations are compared to their control. 
 
2.5.2. Cleavage of p35 to p25 by calcium and arsenite metabolites. 
 
The conversion of p35 to p25 was analyzed by western blot. The transfected HeLa-p35 cells 
were seeded and grown in 6-wells plates and incubated until 80-90% confluence was reached. 
To investigate cleavage of p35 to p25, cultures were stimulated with either CaCl2 in a range of 
0 to 2 mM or arsenite metabolites at end concentrations of 10 or 30 µM (without addition of 
any CaCl2) for 4 hours in the incubator at 37˚C in a 5 % CO2 atmosphere. For inhibition 
experiments, calpeptin, a cell-permeable calpain inhibitor, was used with an end concentration 
of 50 µM and incubated an hour prior to challenge with various calcium concentrations or 
arsenite metabolites. After treatment, cells were collected for further analysis with SDS-
PAGE and western blot.  
 
2.6. Statistical analysis. 
 
The data for each gene were statistically evaluated for each concentration using SPSS 14.0 for 
Windows. Chi-Squared for non-parametric tests (Kruskal-Wallis test) was performed to 
evaluate the data for concentration and As metabolites as obtained for each gene. A level of 
p<0.05 was accepted as statistically significant. 
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3. Results 
 
3.1. Relative Quantification of various genes. 
After treament of the transfected cells with various arsenic metabolites, relative quantification 
indicated that the significant changes on RNA levels were caused by arsenite metabolites on 
the increase of p35 gene expression (p<0.05) (Fig. 1A-C). Gsk3ß was significantly increased 
in its incubation only after incubation with iAsIII (p<0.05).  Arsenate metabolites did not cause 
significant changes in the expression levels of any of the genes. The presence of the genes 
coding for calpain (76 and 80 kDa), CDK5, GSK3ß and the transfected p35 proteins was 
confirmed using the appropriate antibodies (Fig. 1D). 
 
  
1A.      1B. 
   
1C.      1D. 
Fig. 1. Effect of various arsenic metabolites, iAs (1A), MMA (1B) and DMA (1C) and concentrations on the 
various genes involved in phosphorylation of cytoskeletal proteins (*, p<0.05). Relative mean values ± SD; n=6. 
Fig. 1D shows the presence of the µ- and m-calpain, CDK5, GSK3β and the transfected p35 proteins in HeLa 
cell line. 
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3.2. Cleavage of p35 to p25 by calcium and arsenite metabolites. 
 
Calcium induced proteolytic cleavage of p35 from 0.25 mM upwards (Fig. 2A). The arsenite 
metabolites caused a cleavage of p35 to p25 at concentrations of 10 and 30 µM of each 
metabolite. 
 
 
2A. 
 
2B. 
Fig 2. Cleavage of p35 to p25. A titration series of Ca2+ ranging from 0 to 2 mM shows that a minimum 
concentration of 0.25 mM of Ca2+ is needed for the cleavage (2A). All three arsenite metabolites (without 
addition of any CaCl2) cleave p35 to p25 at concentrations of 10 and 30 µM (2B). 
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3.3. Inhibition of p35 cleavage to p25 by calpeptin. 
 
Pretreatment of the transfected cells with 50 µM calpeptin inhibited the cleavage of p35 to 
p25 after incubation of calpeptin with various Ca2+ concentrations (Fig. 3A) and 10 and 30 
µM concentrations of arsenite metabolites (Fig. 3B). 
  
 
3A. 
 
3B. 
Fig 3. Cleavage of p35 to p25 is inhibited by pretreatment with 50 µM of calpeptin. Titration series of Ca2+ 
ranging from 0 to 2 mM shows no cleavage to p25 is visible after Ca2+ treatment (3A). The arsenite metabolites 
(without addition of any CaCl2) are not able to cleave p35 to p25 at concentrations of 10 and 30 µM after pre-
incubation with calpeptin (3B). 
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4. Discussion 
 
A number of metal compounds, such as lead and mercury are known to induce neurotoxicity. 
The organic mercury compound methylmercury has been shown to induce the cleavage of p35 
to p25 after treatment of neuronal cells through calpain activation (Sakaue et al.; 2005). 
In this in vitro study, we first evaluated RNA expression profiles of µ-calpain (calpain-I), m-
calpain (calpain-II), cdk5, gsk3β and p35 after treatment with various arsenic metabolites. 
These genes are involved in hyperphosphorylation and degradation of some of cytoskeletal 
proteins in the nerves. The p35 RNA expression levels were significantly (p<0.05) increased 
after incubation with all the arsenite metabolites at 10 and 30 µM, while GSK3β expression 
was only significantly (p<0.05) induced by iAsIII (Fig. 1A-C). However, the arsenate 
metabolites had no significant effects on any of the gene expression levels. The transfected 
HeLa cells were also used to characterize their protein expression of the used genes as basis 
of our model (Fig. 1D). 
In our previous study in rats, we showed that NF-L protein expression was decreased after 
treatment with iAsIII (Vahidnia et al. 2006), while its expression on RNA level was unchanged 
after treatment with iAsIII in vitro (Vahidnia et al. 2007). This suggests that the reduced 
expression is a post-translational activity. Calpain could be responsible for NF-L degradation, 
since neuroblastoma cells (SY-5Y) treated with arsenic trioxide (trivalent As) show an 
increase in intracellular calcium (Florea et al. 2007). Furthermore, cleavage of p35 to p25 is a 
Ca2+-induced conversion by calpain, which is seen in AD patients (Lee et al. 2000). Here we 
have shown that Ca2+ induces cleavage of p35 to p25 (Fig. 2A) and p25 overexpression after 
incubation with various arsenite metabolites and 10 and 30 µM concentrations (Fig. 2B). This 
is in agreement with other studies that show the breakdown of cdk5/p35 into cdk5/p25 
increases its kinase activity and neurotoxicity (Camins et al., 2006) 
Other studies with PC12 cells under oxidative stress circumstances have shown an increase of 
calcium in the cells and up-regulation of calpain leading to degradation of NF-L protein (Ray 
et al. 2000). Furthermore, inactivation of calpain by calpain inhibitor (MDL-28170) prevents 
NF-L breakdown (Kunz et al. 2004; Lopez-Picon et al. 2006). These results suggest that As-
induced destabilization and disruption of the cytoskeletal framework is partly due to 
activation of calpain, through influx of Ca2+, which in turn is responsible for NF-L 
degradation in a calcium-induced proteolytic process. Here we have shown that inhibition of 
calpain by 50 µM calpeptin prevented both Ca2+- and arsenite-induced cleavage of p35 to p25 
(Fig. 3A and 3B). 
From these results can be concluded that arsenite treated cells show cleavage of p35 to p25, 
which is probably mediated by an increase of Ca2+ in the cells. An increase in internal Ca2+ 
levels and subsequent calpain activation may be the primary step in the mechanism of 
arsenite-induced their neurotoxicity. In addition, calpain splits p35 into p25, which in turn is a 
hyper-activator of CDK5. This p25/CDK5 complex is responsible for the 
hyperphosphorylation of MAP-tau and NF proteins.  Although RNA expression levels of cdk5 
are unaffected with the various arsenic metabolites (Fig. 1A-C), a complex of p25/CDK5 has 
shown to be responsible for hyperphosphorylayion of tau proteins (Lee et al. 2000; Town et 
al. 2002). Hyperphosphorylation of tau reduces its ability to associate with microtubuli 
proteins as their organizer as it has been seen in AD patients (Kesavapany et al. 2003).  
Degradation and hyperphosphorylation of neuronal proteins may lead to disruption of 
neurofilament organization, resulting in pathophysiological changes in the axon. In 
conclusion, we have proposed a mechanism of AsIII-induced neurotoxicity. Future studies will 
show how Ca2+-influx is affected by arsenite metabolites.  
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Abstract 
 
In this study, we investigated the cytotoxic effects of inorganic As (arsenate, iAsV; arsenite, 
iAsIII) and the methylated As metabolites monomethylarsonic acid (MMAV), 
monomethylarsonous acid (MMAIII) dimethylarsenic acid (DMAV) dimethylarsinous acid 
(DMAIII) in three different Chinese hamster ovary (CHO) cell types: AA8 (wild type), UV20 
(ERCC1 deficient) and UV5 (ERCC2 deficient). The As metabolites were applied at different 
concentrations (0 to 100 µM) for 24 hours (n=6). Cytotoxic effects were measured with 
sulphorhodamine B as an indicator for the number of cells that survived in comparison to the 
controls. Our results show that in the selected concentration range pentavalent As metabolites; 
iAsV, MMAV and DMAV are not cytotoxic, unlike the trivalent As metabolites; iAsIII, MMAIII 
and DMAIII. The measured LC50 demonstrated a significant difference (p<0.001) for each 
trivalent metabolite between the three cell lines. UV5 cells also showed a higher resistance to 
MMAIII and DMAIII in comparison to AA8 and UV20 cells, whereas iAsIII demonstrated a 
higher level of cytotoxicity than MMAIII and DMAIII in comparison to AA8 and UV20 cells. 
This might be explained through the generation of hydrogen peroxide (H2O2), which is 
generated by increase of interacellular Ca2+ level. Generation of H2O2 after incubation with 
MMAIII and DMAIII is significantly lower than iAsIII (p<0.01). In conclusion, absence of 
ERCC2 leads to a reduced generation of H2O2 by DMA
III and increased H2O2 generation by 
iAsIII in UV5 cells, which is in contrast to AA8 and UV20 cells. 
 
 
Keywords: arsenite and arsenate metabolites, ERCC1, ERCC2, hydrogen peroxide. 
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1. Introduction 
 
The very elements in the environment - food, water and air - that are a source of life for man 
also expose him to arsenic (As) and its derivatives. Arsenic exposure is associated with 
hypertension, cancer and neurological impairment. Its effect on DNA is indirect, through 
inhibition of DNA repair mechanisms. Nucleotide excision repair (NER) is a major DNA 
repair pathway that removes DNA lesions. Arsenic (As) is an environmental chemical of high 
concern for human health (ATSDR, 2005) and it is a potent toxicant that may exist in trivalent 
(arsenites) or pentavalent (arsenates) oxidation states and in a number of inorganic and 
organic forms. Arsenic cannot be destroyed in the environment. It can only change its form, 
or become attached to or separated from particles. It may change its form by reacting with 
oxygen or other molecules present in air, water, or soil, or by the action of bacteria that live in 
soil or sediment. In many species, arsenic metabolism is characterized by two main types of 
reactions: (1) reduction reactions of pentavalent to trivalent arsenic, and (2) oxidative 
methylation reactions in which trivalent forms of As are sequentially methylated to form 
monomethyl- (MM-) and dimethyl- (DM) products: iAsV → iAsIII → MMAV → MMAIII → 
DMAV → DMAIII. Although there may be differences in the potency of different chemical 
forms, it is generally considered that arsenites tend to be more toxic than arsenates, and 
inorganic is more toxic than the organic forms (Aposhian, 1997). Many studies have shown 
that As can cause DNA damage both in vitro and in vivo (Nesnow et al., 2002; Schwerdtle et 
al., 2003; Palus et al., 2005). Trivalent inorganic As can promote mutagenicity and 
carcinogenicity of other carcinogens and trivalent As species have high affinity for thiol-
groups in proteins. Considerable attention has focused on its interference with DNA repair, 
especially the nucleotide excision repair (NER) pathway (de Laat et al., 1999; Andrew et al., 
2003), whereas less is known about the effect of arsenic on the induction of DNA damage by 
other agents.  
Trivalent arsenic metabolites are a human carcinogen reported to inhibit DNA repair (Walter 
et al., 2007). The binding of arsenites to functional thiol groups of DNA repair enzymes has 
in the past been suggested as a possible mechanism for the effect of arsenites on DNA repair 
(Snyder and Lachmann, 1989). 
The focus of the present study is to evaluate the importance of excision repair cross-
complementing 1 and 2 (ERCC1 and ERCC2) in the cytotoxic effects of various As 
metabolites (iAsIII, iAsV, MMAIII, MMAV, DMAIII and DMAV). To that end, ERCC1 and 
ERCC2 deficient cell types were compared to wild type after incubation with various As 
metabolites and concentrations.    
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2. Material and methods 
 
2.1 Chemicals 
 
The following arsenic metabolites and chemicals were purchased from Sigma-Aldrich (St. 
Louis, MO, USA): Sodium meta-arsenite (AsIII) (catalog no. 228699-100G), Arsenic acid 
sodium (AsV) (catalog no. A6756-50G), Trypsin-EDTA solution 1x (catalog no. T3924). 
Dimethyl arsenic acid (DMAV) (catalog no. PS-51) and Disodium methyl arsenate (MMAV) 
(catalog no.: PS-281) were obtained from Chem Service (West Chester, PA, USA). 
Methylarsinous diiodide (MMAIII) and Dimethylarsinous iodide (DMAIII) were purchased 
from Dr. Cullen of the Department of Chemistry at the University of British Columbia, 
Vancouver, Canada. 
 
2.2. Cell cultures 
 
Three different Chinese hamster ovary (CHO) cell lines; AA8 (wild type; ATCC no. CRL-
1859TM), UV20 (ercc1 deficient; ATCC no. CRL-1862TM) and UV5 (ercc2 deficient; ATCC 
no. CRL-1865TM) were purchased from American Type Culture Collection-ATCC (Manassas, 
VA, USA). Most of the materials for cell culture were purchased from Invitrogen (Breda, 
Netherlands); other more specific details are enclosed in brackets. The cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM, catalog no. 41966) and supplemented with 
10% heat-inactivated fetal bovine serum obtained from Greiner bio-one GmbH (catalog no. 
758093) (Frickenhausen, Germany), in turn supplemented with 100 IU/ml 
penicillin/streptomycin (catalog no. 15140-122), and maintained at 37 °C, 5% CO2 in a 
humidified incubator. 
 
2.3. Growth inhibition assay 
 
Cytotoxicity to As metabolites were assessed using the sulphorhodamine B (SRB)  growth 
inhibition assay for each As metabolites. Cytotoxicity was determined by assessing their 
median lethal concentration (LC50). SRB was used as an indicator for the number of cells that 
survived in comparison to the controls. On two different occasions, cells were cultivated in 
triplicate for each As metabolite and concentration in a 96-wells plate (n=6). A total of 
1.2 × 103 cells (AA8, UV20, UV5) were seeded into each well of 96-well plates in a volume 
of 150 µl and incubated at 37°C overnight. Arsenic concentrations of 0, 1, 3, 10, 30, and 100 
µM were prepared in culture medium immediately before use and 50µl of drug-medium 
mixture was added to the appropriate wells. Plates were incubated for 24 h at 37°C. Following 
drug treatment, the medium was replaced with 200 µl of fresh complete medium, and the 
plates were incubated for 3 days at 37°C. The growth medium in the wells was removed, and 
50 µl of ice-cold 50% (w/v) trichloroacetic acid was added to fix the cells for 1 hour at 4°C. 
The cells were subsequently washed six times with MQ-H2O and stained with 50
 µl of 0.4% 
(w/v) SRB-1% acetic acid for 20 min. at room temperature. Unbound dye was removed by 
washing 6 times with 1% acetic acid, and plates were dried. The dye was dissolved by the 
addition of 150 µl of 10 mM Tris-base into each well. Plates were incubated for 20 min. at 
room temperature, and the optical density (OD) at 570 nm was measured with the 
SpectraMAX 250 Microplate Spectrophotometer from Molecular Devices (Wokingham, UK) 
(Fig. 1A-C).  
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2.4. Detection of peroxide generation 
 
Peroxide generation by As metabolites was assessed using dihydrorhodamine 123 (DHR123) 
as an indicator for H2O2 generation through its conversion to rhodamine 123 (R123) 
(Sakurada et al. 1992; Smit et al. 2006). From each cell line, the same amount of cells –1.104 
– was added in 0.2 ml medium into each well on a 96-wells plate and incubated for 24 h at 37 
ºC in a 5% CO2 incubator. Two 96-wells plate in triplicate (n=6) were incubated with the 
various trivalent As metabolites at a concentration of 3 µM and 1 µM DHR123 for duration of 
4 hours. The fluorescence absorbance caused by conversion of DHR123 to R123, was 
analyzed by PerkinElmer model Victor2 1420-012 Multilable Counter (Groningen, 
Netherlands) in the 96-wells plates at 485/535 nm (Fig. 2). 
 
2.5. Statistical analysis. 
 
The LC50 and the H2O2 generation in the three cell lines were statistically evaluated for each 
metabolite using the SPSS 14.0 for Windows. Chi-square for non-parametric tests (Kruskal-
Wallis test) was performed to evaluate the data. A level of p<0.05 was accepted as 
statistically significant. 
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3. Results 
 
3.1. Growth inhibition assay 
 
The LC50 was determined only for trivalent As metabolites, since pentavalent As metabolites 
did not reach complete lethality at the highest concentration of 100 µM. The LC50 estimation 
was carried out by plotting the measured absorbance associated with the different 
concentrations (Fig 1A-C). The LC50 values for each trivalent As metabolite are shown in 
Table 1.  
 
   
1A.       1B. 
 
1C.  
Fig 1. The increasing concentrations of the three trivalent arsenic metabolites iAsIII (A), MMAIII (B) and DMAIII 
(C) results in decreased sulphorhodamine B (n=6 for each concentration). The data obtained from the growth 
inhibition assay are used to determine the LC50.   
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Table 1. LC50 of various metabolites in three different CHO cell types. 
 
 
Metabolite (n=6)  AA8   UV20   UV5 
 
iAsIII    38.2 ± 5.6  30.9 ± 3.4  14.9 ± 1.4  
  
MMAIII     4.9 ± 0.3    4.8 ± 0.2    6.9 ± 0.3 
 
DMAIII     1.5 ± 0.1    1.5 ± 0.1    2.1 ± 0.1 
 
 
Each arsenite metabolite (iAsIII, MMAIII, and DMAIII) showed significant differences between 
the three CHO cell types (p<0.001). Mean values (± SD) for the number of determined LC50 
(n=6). 
At 100µM, no significant cell death was observed for iAsV, MMAV, and DMAV.  Therefore, 
their LC50 could not be determined.  
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3.2. H2O2 generation by arsenite metabolites 
 
Hydrogen peroxide generation, as a result of incubation with 3 µM arsenite metabolites, was 
measured and expressed as mean fold increase (MFI). They demonstrated a significantly 
(p<0.01) higher H2O2 generation by iAs
III in UV5 cells was increased 3.45 MFI), while 
generation by iAsIII was only increased by 2.31 and 2.33 MFI in AA8 and UV20, 
respectively. The H2O2 generation by MMA
III showed no significant increase between the 
three cell lines, 2.83, 2.69 and 2.81 MFI for AA8, UV20 and UV5, respectively.  The H2O2 
generation by DMAIII was significantly (p<0.01) increased for the three cell lines in 
comparison to control, 3.87, 2.97 and 1.41 MFI for AA8, UV20 and UV5, respectively (Fig. 
2).  
 
 
Fig 2. Mean fold increase of hydrogen peroxide generation by various As metabolites (± SD; n=6). Arsenite 
metabolites iAsIII DMAIII, showed a significant difference (p<0.01, *) between the various cell types (AA8, 
UV20 and UV5) at 3 µM concentration and control groups. However, incubation with MMAIII showed no 
significant changes.  
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4. Discussion 
 
Nucleotide excision repair is a major DNA repair pathway that removes DNA lesions 
including certain DNA crosslinks, UV photolesions and bulky chemical adducts (Mullenders 
et al., 2001). Arsenic affects expression of a variety of genes through modification of the 
transcription factor expression and activity as well as the methylation status of the cell 
(Hughes, 2002). 
The LC50 results are evaluated in two different manners. On the one hand, we examined each 
As metabolite separately in the three cell types (Table 1, per row), and on the other, we 
checked the effects of the three metabolites per cell type (Table 1, per column). Our results 
showed that the absence of ERCC1 did not contribute to the cytotoxic effects of the arsenite 
metabolites in comparison to wild type (Table 1). The mono- and dimethylated arsenites were 
significantly more cytotoxic to the AA8 and UV20 (ERCC1 deficient) cells (p<0.001). The 
differences between the metabolites per cell type are also statistically significant (p<0.001). 
The UV5 cells, which are ERCC2 deficient, showed more resistance to methylated arsenites 
in comparison to AA8 and UV20 cells. Results could be summarized as follows: in CHO 
cells, methylated arsenites are more cytotoxic than its inorganic form. However, iAsIII is more 
cytotoxic to UV5 cells than to AA8 and UV20 cells. Whereas, MMAIII and DMAIII are less 
cytotoxic to UV5 cells than AA8 and UV20 cells. 
Production of reactive oxygen species (ROS), such as hydroxyl radicals (OH˙), superoxide 
anions (O2
−), and hydrogen peroxide (H2O2), are a normal byproduct of aerobic metabolism in 
all eukaryotic organisms. However, elevation of intracellular ROS may also occur through 
exposure to environmental toxicants, such as arsenic (Schwerdtle et al., 2003; Hei and Filipic, 
2004).  
The measured LC50 for AA8 (wild type) and the UV20 (ERCC1 deficient) cells show more or 
less the same cytotoxicity pattern with the three arsenite metabolites in contrast to UV5 
(ERCC2 deficient) cell type. A possible explanation can be deduced from the levels of H2O2 
generation in the CHO cells. At a concentration of 3 µM of arsenite metabolite, the measured 
H2O2 generation in MFI for iAs
III was somewhat higher in UV5 cells (3.45 MFI) in 
comparison to AA8 and UV20 cells (2.31 and 2.33, respectively). The H2O2 generation by 
MMAIII in all three cell lines was significantly increased in comparison to controls but not in 
comparison to each other. This correlates with the determined LC50’s in all three cell lines.
 
The measured H2O2 generation in MFI for DMA
III was somewhat lower in UV5 cells (1.41 
MFI) in comparison to AA8 and UV20 cells (3.87 and 2.97, respectively).  
As yet, it is not clear why the absence of ERCC2 leads to a reduced generation of H2O2 by 
DMAIII and increased H2O2 generation by iAs
III in UV5 cells, which is in contrast to AA8 and 
UV20 cells. However, all eukaryotic organisms have multiple cellular mechanisms to prevent 
the excessive accumulation of ROS and protect against their harmful effects. Antioxidant 
defense mechanisms include those that involve nonenzymatic molecules such as glutathione 
and several vitamins, as well as ROS scavenger enzymes such as superoxide dismutase and 
catalase, and glutathione peroxidase (Anderson and Phillips 1999). Ercc2 protein is also a 
subunit of the basal transcription factor TFIIH, a large complex involved in the initiation of 
transcription, unlike ercc1 protein. It is possible that the absence of ERCC2 in UV5 cells and 
its involvement in the initiation of transcription, could lead to a compensatory mechanism by 
which these antioxidants are more active. This possibility is currently under investigation. 
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General Discussion and Summary 
 
 
Arsenic 
Arsenic is a metalloid with the symbol As and atomic number 33. It has an atomic mass of 
74.92. It has been known since ancient times, though probably in compound form rather than 
in its pure state. Arsenic has a long history of medical applications; before penicillin was 
developed an arsenic compound was used to treat syphilis. Arsenic has also been used in 
combination with other materials in pigments, poison gases and insecticides (such as Paris 
Green, calcium arsenate, lead arsenate and lewisite as chemical agent for warfare) and is well 
known from former use as a rat poison. In forensic science, it is well-known from a great 
number of homicidal cases over many centuries. Arsenic is known to be used as a 
preservative in tanning and taxidermy, as well as in Wolman’s salt as a wood preservative and 
even playground materials. Other uses of As compounds are or have been used in ammunition 
manufacturing. Its use in combination with other metals helps to improve the hardness of 
bullets.  
Arsenic is a notoriously poisonous metalloid with known hazardous effects to human health. 
The element exists in both organic and inorganic forms and either form can also exist in 
trivalent (-3, +3 or arsenite, AsIII) or pentavalent oxidation state (+5 or arsenate, AsV). In 
many animal species arsenic metabolism is characterized by two main types of reactions: (1) 
reduction reactions of pentavalent to trivalent arsenic, and (2) oxidative methylation reactions 
in which trivalent forms of As are sequentially methylated to form monomethyl- (MM-) and 
dimethyl- (DM) products: iAsV → iAsIII → MMAV → MMAIII → DMAV → DMAIII. 
Although there may be differences in the potency of different chemical forms, it is generally 
considered that arsenites tend to be more toxic than arsenates and inorganic is more toxic than 
the organic form. Intoxication with As may occur in the acute (short-term) and chronic (long-
term) forms, which are separate syndromes. Acute As exposure may cause nausea, vomiting, 
diarrhea, weakness, loss of appetite, shaking, cough, headache and neuropathy. Chronic 
exposure may lead to a variety of symptoms including skin pigmentation, numbness, and 
cardiovascular disease. It is also known to cause various forms of cancer such as skin (non-
melanoma type), kidney, bladder, lung, prostate and liver cancer and, again, neuropathy.  
The presence and levels of As can be analyzed in urine, blood and hair. Tests may either be 
devised to measure the total As content in tissues or bodyfluids, or the different types of 
arsenic species. For total As concentration measurement is carried out with atomic absorption 
spectrometry (AAS) in various samples. Atomic absorption spectroscopy is based on the 
absorption of light to measure the concentration of gas-phase atoms. Since samples are 
usually liquids or solids, the analyte atoms or ions must be vaporized in a flame or graphite 
furnace. The atoms absorb ultraviolet or visible light and make transitions to higher electronic 
energy levels. The analyte concentration is determined from the amount of absorption. 
Applying the Lambert-Beer law directly in AAS is difficult due to variations in atomization 
efficiency from the sample matrix, and non-uniformity of concentration and path length of 
analyte atoms (in graphite furnace AAS). Concentration measurements are usually determined 
from a calibration curve after calibrating the instrument with standards of known 
concentration. Prior to quantification of the analyte by AAS it is usually necessary to destroy 
the organic matrix and bring the element into inorganic solution. In many cases, As samples 
are usually predigested with a digestive acid such as a mixture of perchloric and nitric acid 
(Sakamoto et al. 2001). The samples for As analysis prior to measurements are added to the 
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calibration matrix consisting of 1M HCl (reduction acid) in order to convert all the 
pentavalent to trivalent As.  
When studying the hazardous effects of various As metabolites, determination of total arsenic 
concentration needs to be completed with the analysis of individual arsenic species and 
compounds. Various techniques such as high pressure liquid chromatography (HPLC) 
coupled with ICP-MS, ICP-AES or AAS are most suitable for the quantification of arsenic 
species (Londesborough et al. 1999).  
 
Arsenic and neurotoxicity 
Exposure to As may affect both the central and peripheral nervous systems; symptoms 
include tremors, headaches, numbness, irritability, muscular weakness, convulsions and 
coma. Although peripheral nervous system (PNS) impairment is common in As-exposed 
populations, its mechanism is poorly understood. Arsenic effects manifest themselves weeks 
after first exposure as both central and peripheral neuropathy. The most frequent neurological 
manifestation by As is peripheral neuropathy that may last for several years, if not life-long. 
Peripheral neuropathy may lead to rapid severe ascending weakness, similar to the Guillain-
Barré syndrome, requiring mechanical ventilation (artificial respiration). From human clinical 
cases studied by Le Quesne and McLeod (1977) it has become clear that As exposure results 
in a late reaction of the nervous system, which was established by decrease in their nerve 
conducting velocity (NCV) measurements (Le Quesne & McLeod 1977). Patients exposed to 
As show significantly lower Nerve Conduction Velocities (NCVs) in their peripheral nerves 
in comparison to their referents (Greenberg 1996; Tseng et al. 2006; Otto et al. 2007). 
Although this reduction in NCV is a hallmark in As-induced neurotoxicity, its mechanism of 
action on the molecular level is not known. Therefore, the project described in this thesis was 
aimed at elucidating the probable mechanism of As-induced neurotoxicity in animals in vivo 
and in cell cultures in vitro. 
The animal studies in this thesis were designed to answer questions about the effect of As on 
the peripheral nervous system after sub-acute and chronic intoxication of laboratory rats. 
Axonal integrity is maintained by three categories of cytoskeletal proteins: neurofilaments, 
which are found in high concentrations along the axons, microtubules and actin filaments 
(microfilaments). Neurofilaments are specific to neurons and found in high concentrations 
along the axons of vertebrate neurons. Three types of neurofilament proteins exist, which co-
assemble in vivo, forming a heteropolymer that contains Neurofilament-Light (NF-L, 68 kDa) 
plus either Neurofilament-Medium (NF-M, 150 kDa) or Neurofilament-Heavy (NF-H, 200 
kDa) proteins. During axonal growth, new neurofilament subunits are incorporated all along 
the axons. In an intact nerve, the level of neurofilament proteins control how fast electrical 
signals travel down the axon. Microtubules consist of tubulin subunits. Their stability is 
regulated by the interaction with microtubule-associated proteins (MAPs). MAP function 
includes both stabilizing and destabilizing microtubules, guiding microtubules toward specific 
cellular locations, cross-linking microtubules and mediating the interactions of microtubules 
with other proteins in the cell. MAP-tau is a microtubule-associated protein, which is 
primarily expressed in neurons. They are required for tubulin assembly into the microtubules 
and stabilize the assembled microtubules. 
Chapter 3 of this thesis describes the compositional changes in rat sciatic nerves after a single 
exposure to arsenite i.v. with various doses. As a first step in this study, the short- and long-
term effects of arsenite on rat sciatic nerve proteins were studied as a model for peripheral 
axonopathy. Male Wistar rats were exposed to inorganic arsenite (iAsIII) given as a single 
dose i.v. dissolved in PBS (between 0 and 20 mg/kg) in a tail vein. The doses used for short-
term single arsenic exposure were 0-, 15- and 20-mg/kg iAsIII (n=3). The long-term single 
exposures were 0-, 3- and 10-mg/kg iAsIII (n=9). In the short-term section of the experiment, 
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rats were kept in metabolic cages for the intended duration of 3, 6 and 9 hours. In the long-
term section of the experiment, rats were kept in metabolic cages 24 hours after injection. 
Afterward, rats that received the same dose were combined into one group and housed for 2, 3 
and 4 weeks in plastic cages on sawdust. The difference between the long- and short-term 
studies is the result of the variation in dose range and the duration of urine collection. After 
sacrifice, sciatic nerves were excised and the protein composition was analyzed. Protein 
analysis of sciatic nerves showed disappearance of neurofilament and fibroblast proteins in 
rats treated with arsenite doses of 15 and 20 mg/kg in comparison to the control groups. Some 
fibroblast protein bands with band sizes of 40 and 140 kDa degraded after a high dosage in 
the 20-mg/kg dose group. The analyzed neurofilament-M and -L proteins decreased dose-
dependently over time. Arsenic affects the composition of proteins in the rat sciatic nerve, 
especially the neurofilaments. The reduction of signals in western blot analysis revealed 
changes in cytoskeletal composition, which may well lead to neurotoxic effects in vivo. 
Chapter 4 of this thesis describes studies on the compositional changes in rat sciatic nerves 
after semi-chronic exposure. In our previous study in rats exposed to As, we observed an 
effect of As on neurofilaments in the sciatic nerve. This study deals with the effects of iAsIII 
in Wistar rats on the cytoskeletal protein composition of the sciatic nerve after subchronic 
intoxication. Inorganic arsenite dissolved in phosphate-buffered saline (PBS) was orally 
administered daily in doses of 0, 3 and 10 mg/kg body weight/day (n = 9 rats/group) by 
intragastric route for 4, 8 and 12 week periods. The control group received only PBS without 
added arsenite. Toxicokinetic measurements revealed a saturation of blood As levels in the 3- 
and 10-mg/kg dose groups at approximately 14 µg/ml, with an increase in renal clearance of 
As at increasing doses. After exsanguination, sciatic nerves were excised and the protein 
composition was analyzed. Analysis of the sciatic nerves showed compositional changes in 
their proteins. Protein expression of NF-H and NF-M remained unchanged. Neurofilament 
protein Low (NF-L) expression was reduced, while µ- and m-calpain protein expression was 
increased, both in a dose/time pattern. Furthermore, NF-H protein was hypophosphorylated; 
while NF-L and microtubule-associated protein tau (MAP-tau) proteins were phosphorylated.  
These two in vivo studies present direct evidence for the As effect on the neuronal skeleton, as 
a basis for neurotoxicity. The first real proof of As involvement was the elevated As 
measurements in the sciatic nerve tissues of the rats in sub-acute and semi-chronic induced-
toxicity in these rats. The second evidence was achieved by the decrease in cytoskeletal NF-L 
protein. Several studies that were performed to elucidate the role of neurofilament proteins 
have concluded that both NF-H and NF-M each need a NF-L protein to form a heteropolymer 
(Carpenter & Ip 1996). The third evidence was achieved through the (hyper) phosphorylation 
of MAP-tau and NF-L. Phosphorylation of the MAP-tau and NF-L proteins leads to 
conformational changes leading to destabilization and disruption of the cytoskeletal 
framework. These results suggest that the mechanism of As induced-neurotoxicity lays in the 
cytoskeletal proteins that have been affected by As in various ways. 
In the in vitro studies, effects of other As species were tested in various cell culture models 
(chapter 5) and the manner of their hyperphosphorylation was further studied (Chapter 6) for 
a better understanding of the disruption of neuroskeletal integrity by As. 
Chapter 5 of this thesis describes the effects of various arsenic metabolites (iAsIII, iAsV, 
MMAV and DMAV) on two different cell lines derived from the peripheral (ST-8814) and 
central (SK-N-SH) nervous system. The effects of As metabolites were examined on the 
relative quantification levels of the cytoskeletal genes, neurofilament-light (NEFL), 
neurofilament-medium (NEF3), neurofilament-heavy (NEFH) and microtubule associated 
protein-tau (MAPT), using Real-Time PCR. Various As metabolites (iAsIII, iAsV, MMAV and 
DMAV) and concentrations of 0, 0.3, 1.0 and 3.0 µM dissolved in their appropriate cell culture 
Chapter 8 
 112
medium were incubated for 24 and 48 hours in triplicate. Afterward, cDNAs were synthesized 
from the isolated RNA to determine their relative quantification (RQ) and follow the changes 
in expression of these genes under influence of the various As metabolite and concentrations. 
Our results showed that iAsIII and iAsV have no significant effects on either cell lines. 
Conversely, MMAV and DMAV cause significant changes in expression levels of NEF3 and 
NEFL genes, while the expression level of the NEFH gene is significantly increased in both 
cell lines. Increase in NF-H may suggest a compensatory mechanism. However, this needs 
further study.  
In chapters 3 to 5 we have demonstrated that arsenic metabolites change the composition of 
cytoskeletal proteins in vivo and in vitro. Furthermore, in chapter 4 we demonstrated that 
calpain expression is increased with the increase of As dose and exposure time. To further 
examine the mechanism of arsenic-induced neurotoxicity with various As metabolites (iAsIII, 
iAsV, MMAIII, MMAV, DMAIII and DMAV), we studied the role of p35 and calpain enzyme 
(chapter 6) and its involvement in hyperphosphorylation of cytoskeletal proteins. Calpain is a 
calcium-activated cytoplasmic protease that seems to be involved in some neurodegenerative 
diseases such as Alzheimer disease (AD) (Lee et al. 2000). Alzheimer patients form 
neurofibrillary tangles through tau hyperphosphorylation. Calpain has also been shown to be 
responsible for NF-L degradation, since neuroblastoma cells (SY-5Y) treated with arsenic 
trioxide (trivalent As) show an increase in intracellular calcium (Florea et al. 2007). Studies in 
PC12 cells under oxidative stress circumstances have shown an increase in calcium within the 
cells and up-regulation of calpain leading to degradation of NF-L protein (Ray et al. 2000). 
Moreover, inactivation of calpain by calpain inhibitor (MDL-28170) prevents NF-L 
breakdown (Kunz et al. 2004; Lopez-Picon et al. 2006). These results suggest that As-induced 
destabilization and disruption of the cytoskeletal framework is partly due to increased 
expression of calpain, which in turn is responsible for NF-L degradation in a calcium-induced 
proteolytic process. 
Another approach to destabilization and disruption of the cytoskeletal framework is through 
phosphorylation of cytoskeletal proteins. In a normal situation, p35 binds to cyclin-dependent 
kinase 5 (Cdk5), which is responsible for neurite-outgrowth. In diseased patients, p35 is 
cleaved to p25 by calpain, whereby p25 binds to Cdk5, resulting in hyper-activation of Cdk5 
and hyperphosphorylation of tau and neurofilament proteins (Fig. 1) 
 
 
Fig.1. Cleavage of p35 to p25 by calpain. A. Healthy subjects where complex of p35/cdk5 is responsible for the 
neurite outgrowth. B. Influx of Ca2+ in patients with Alzheimer’s disease, for example, results in activation of 
calpain protease. Calpain cleaves p35 to p25, whereby the p25/Cdk5 complex results in hyperphosphorylation of 
MAP-tau proteins. 
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In chapter 6 (Arsenic Neurotoxicity IV), we tried to examine whether the cleavage of p35 to 
p25 can be induced by As. Furthermore, we studied mRNA expression levels of calpain, 
cyclin-dependant kinase 5 (Cdk5) and glycogen synthase kinase 3 beta (Gsk3ß). A transfected 
HeLa cell line with a p35 construct (HeLa-p35) was used as a model, since all other necessary 
proteins such as calpain, Cdk5 and Gsk3ß are already present in HeLa cells. HeLa-p35 cells 
were incubated with various As metabolites and concentrations of 0, 10 and 30 µM for 
duration of 5 hours, after which the cells were either lysed to analyze p35 protein expression 
or examined on the relative quantification levels of the genes. 
Calpain activation may contribute to As-induced neurotoxicity in two ways. As shown in 
chapter 4, incubation with As leads to hyperphosphorylation of MAP-tau and NF proteins, 
resulting in deregulation and disorganization of the cytoskeletal framework on the one hand. 
On the other, it causes calpain activation-induced degradation of NF-L protein (Kunz et al. 
2004). These authors have shown that calpain inhibition prevents inflammation-induced NF-L 
breakdown in the spinal cord. This may suggest that inorganic arsenic causes degradation on 
the protein level in vivo by activating proteases such as calpain. In chapters 3 and 4, we 
showed that NF-L protein expression was decreased after treatment with iAsIII. It is 
reasonable to suggest that since As results in activation of calpain through influx of Ca2+ that 
calpain is responsible for NF-L degradation in a calcium-induced proteolytic process. The 
results found in our in vivo and in vitro experiments suggest that As exerts its toxic effects in 
two different manners depending on the As species. Rats treated with iAsIII showed a decrease 
in NF-L expression on their protein level, while the in vitro study with iAsIII (chapter 5) 
showed no changes in expression on the mRNA level after treatment with inorganic As.  
 
 
 
Fig. 2. Two probable mechanism of AsIII induced neurotoxicity with involvement of calpain activity. AsIII 
results in decrease of NF-L protein, which could be the result of a calpain-induced proteolytic process. AsIII 
induces hyperphosphorylation of cytoskeletal proteins through calpain-induced activation of the cleavage of p35 
to p25.  
 
Effects of As on the DNA level is not reserved to cytoskeletal genes only. Arsenic is also 
known to be carcinogenic and to be involved in inhibition of DNA repair mechanisms 
(Andrew et al. 2006). However, the carcinogenic mechanism of As has yet to be fully 
understood. Many studies have shown the adverse effects of As on chromosomal and DNA 
level (Colognato et al. 2007; Yedjou & Tchounwou 2007) and to some extent on the effects of 
nucleotide excision repair and As. Andrew et al. (2006) have shown that people exposed to 
As in drinking water have decreased DNA repair abilities, namely the decrease of excision 
repair cross-complementing 1 (ERCC1) (Andrew et al. 2003; Andrew et al. 2006). In chapter 
7 of this thesis, we describe the effect of various As metabolites (iAsIII, iAsV, MMAIII, 
MMAV, DMAIII and DMAV) on three Chinese hamster ovary (CHO) cell lines, AA8 (wild 
type), UV20 (ERCC1 deficient) and UV5 (ERCC2 deficient). Cytotoxicity to the As 
metabolites was assessed by determining the concentration at which 50% of the cells in 
culture is killed (LC50). The LC50 was only determined for trivalent As metabolites, since 
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pentavalent As metabolites did not reach complete lethality at the highest concentration. Our 
results showed that in CHO cells, methylated arsenites are more cytotoxic to AA8 and UV20 
cell types than AsIII in the inorganic form, while absence of ERCC2 in UV5 cell types 
contributes to higher resistance to methylated arsenite species. 
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Achtergrond 
Arsenicum of arseen is een scheikundig element met symbool As en atoomnummer 33. Het 
woord arseen is afgeleid van het Perzische woord zarnikh ( رزHIJ ), dat later via de Arabische 
taal (al-zarnikhu) door de Grieken als Arsenikon (‘αρσενικόν) geïntroduceerd werd in de 
westerse talen. De oude Grieken gebruikten arseen onder meer als make-up. Het element is 
door de eeuwen heen veelal gebruikt voor veel verschillende doeleinden. Arseen is een van de 
oudste giften die de mens bekend zijn. Het werd veelal gebruikt als bestanddeel van tonica in 
de geneeskunde, ook in de huidige traditionele Chinese en Indische geneeskunde. De 
therapeutische waarde van arseen in de vorm van Salvarsan (3.3'-Diamino-4.4'-dihydroxy-
arsenobenzeen) bleek bij de behandeling van syfilis. Een andere toepassing is het gebruik als 
pesticide, dat later werd afgeschaft vanwege de schadelijke bijwerkingen voor de mens. 
Arseen is en wordt ook gebruikt als moordmiddel. Een recent voorbeeld hiervan is de zaak 
van de Indonesische mensenrechtenactivist Munir, die op weg van Jakarta naar Amsterdam op 
7 september 2004 in het vliegtuig dodelijk vergiftigd werd. Misschien een van de meest 
bekende slachtoffers van arseen is Napoleon Bonaparte, die vermoedelijk chronisch vergiftigd 
werd, hetzij opzettelijk, hetzij accidenteel door arseen uit het behang van zijn verbaningsoord. 
Een ander bekend voorbeeld van arseenvergiftiging is het werk van de Leidse gifmengster; 
Maria Catharina van der Linden – Swanenburg, beter bekend als Goeie Mie. Door haar grote 
hulpvaardigheid, waaraan ze ook haar bijnaam "Goeie Mie" dankte, bouwde ze een grote 
kring aan buren, kennissen en vrienden op. Goeie Mie leefde in de 19de eeuw, was getrouwd 
en had twaalf kinderen, maar zes daarvan stierven al op jeugdige leeftijd, zoals in die tijd vaak 
voorkwam. Haar wens voor een minder armoedig bestaan en om aan haar alcohol behoefte te 
kunnen voldoen, leidde tot het stelselmatig vergiftigen van familieleden en buurtbewoners, 
maar niet nadat zij een verzekering op hun leven had afgesloten met zichzelf als begunstigde. 
Tussen 1867 en 1884 vergiftigde zij minstens 102 van de door haar verzekerden met arseen, 
dat ze in de koffie, melk of erwtensoep strooide. Van de vergiftigde mensen werden er 45 
ernstig ziek met neurologische restverschijnselen en 27 mensen overleden als gevolg van 
arseenvergiftiging, waaronder 16 familieleden. 
Arseen komt voor als anorganische en organische verbindingen. Organisch As onderscheidt 
zich van anorganisch As door de aanwezigheid van één of meer methylgroepen aan het 
arseenatoom. Bij één methylgroep spreekt men van monomethyl- (MM-) en bij twee van 
dimethyl- (DM) arseen. Verder kennen deze arseenverbindingen verschillende 
oxidatietoestanden, driewaardig (arseniet; AsIII) en vijfwaardig (arsenaat; AsV). Een algemeen 
geldende regel is dat een anorganische arseenverbinding meer toxisch is dan de 
overeenkomstige gemethyleerde arseenverbinding, en voorts dat het driewaardige arseen 
toxischer is dan de vijfwaardige verbinding. Bij inname van arseen door mensen ondergaat As 
een reeks van metabole stappen waarbij anorganisch arseen wordt omgezet in organisch 
arseen als volgt: 
 
aAsV → aAsIII → MMAV → MMAIII → DMAV → DMAIII 
 
Deze arseenverbindingen komen in variabele hoeveelheden in de natuur voor. Arseen bevindt 
zich in de bodem, en het kan via stof en water in de lucht en op het land terecht komen. 
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Mensen kunnen via voedsel, water en door inademing blootgesteld worden aan arseen. 
Expositie kan ook plaats vinden via huidcontact met besmette grond of water. Bij langdurige 
blootstelling kunnen verschillende aandoeningen ontstaan, zoals ontwikkeling van 
verschillende soorten kanker, variërend van huidkanker tot maligniteiten van de organen en 
natuurlijk neurologische aandoeningen. 
Chronische blootstelling aan arseen is een wereldwijd probleem. Miljoenen mensen in 
Aziatische landen als Bangladesh, India en Taiwan en zelfs in moderne industriële landen 
zoals Amerika en Duitsland hebben gezondheidsproblemen door blootstelling aan arseen. De 
herkomst van arseen kan herleid worden tot het drinkwater in vele derde-wereldlanden, 
waarbij hun drinkwater dat afkomstig is van natuurlijke geologische bronnen is verontreinigd 
met arseen. In het jaar 2000 sloeg de Wereld Gezondheid Organisatie (WHO) groot alarm: de 
helft van de bevolking van Bangladesh werd met ziekte bedreigd door arseenblootstelling. 
Oorzaak van de massavergiftiging waren de miljoenen waterputten die in het kader van een 
WHO-project daar in de afgelopen jaren waren geslagen, bedoeld als verbetering van de 
drinkwatervoorziening. Een concentratie kleiner dan 10 delen per miljard (parts per billion, 
ppb) is volgens de WHO een toelaatbare hoeveelheid arseen in grondwater dat gebruikt wordt 
als drinkwater; helaas komen in vele delen van Bangladesh concentraties hoger dan 50 ppb 
voor.  
 
Arseen en Neurotoxiciteit 
 
Blootstelling aan arseen beïnvloedt zowel het centrale als het perifere zenuwstelsel. Effecten 
op het zenuwstelsel manifesteren zich ondermeer als trillingen, stuiptrekkingen, hoofdpijn en 
gevoelloosheid, spierzwakte en uiteindelijk coma. De meest voorkomende neurologische 
manifestatie van arseenvergiftiging is op het perifere zenuwstelsel. Deze symptomen kunnen 
jarenlang aanhouden, als het niet levenslang is. Deze kenmerken zich vooral door effecten in 
de lagere extremiteiten. Klinische studies in met arseen vergiftigde populaties hebben 
aangetoond dat arseen leidt tot een verlate manifestatie in zenuwen die weken tot maanden 
later waarneembaar is. Bij deze patiënten is de geleidingssnelheid in de zenuwbanen 
aanzienlijk afgenomen in vergelijking tot gezonde mensen. Hoewel deze symptomen bij 
arseenvergiftiging goed beschreven zijn, is het mechanisme van arseen-neurotoxiciteit op 
moleculair niveau niet goed begrepen en onderzocht. Daarom wordt in dit proefschrift 
getracht de mogelijke mechanismen die hieraan ten grondslag liggen te vinden en verklaren. 
De opzet van de studies die beschreven staan in dit proefschrift is tweeledig. Enerzijds hebben 
zij plaats gevonden in ratten (in vivo) als model voor het aantonen van effecten van 
anorganisch arseniet (aAsIII) op zenuwen op eiwitniveau (hoofdstuk 3 & 4). Anderzijds zijn 
studies uitgevoerd in neuronale en niet-neuronale cellen (in vitro) voor nader onderzoek van 
effecten van verschillende arseenverbindingen op moleculair niveau (Hoofdstukken 5, 6 & 7). 
De studies in ratten waren ontworpen ter verduidelijking van acute en subchronische effecten 
van arseen op de axonen van het perifere zenuwstelsel. Veranderde axonale integriteit kan een 
mogelijke verklaring en benadering zijn ter verduidelijking van het mechanisme van arseen in 
de zenuwen. Axonen bevatten structuren die zijn samengesteld uit een aantal eiwitgroepen, 
deze zorgen voor de integriteit en het transport in de zenuwen. Dit zogenaamde cytoskelet is 
opgebouwd uit neurofilamenten, microtubuli en actine-filamenten (microfilamenten). 
Neurofilamenten zijn specifiek voor neuronen en ze zijn in grote hoeveelheden aanwezig in 
de neuronen. Er bestaan drie soorten neurofilament-eiwitten die samen een netwerk van 
heteropolymeren maken; neurofilament-laag (NF-L; 68 kDa), neurofilament-medium (NF-M; 
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150 kDa) en neurofilament-hoog (NF-H; 200 kDa). Bij een intact neuron controleert dit 
netwerk van neuronfilament-eiwitten het elektrische signaal en het axonale transport. 
Microtubuli bestaan uit tubuline-eiwitten. De stabiliteit van deze microtubuli wordt 
gereguleerd door interacties met microtubulus-geassocieerde eiwitten (MAPs), met MAP-tau 
als neuron-specifieke vorm.  
In hoofdstukken 3 & 4 worden de resultaten weergegeven van onderzoek naar de effecten van 
arseen op deze eiwitten in ratten. Hoofdstuk 3 beschrijft het acute effect van aAsIII na 
intraveneuze toediening die leidt tot verandering van eiwitsamenstelling in de heupzenuw (N. 
ischiadicus). De hoogste doseringen van 15 en 20 mg/kg leiden tot afname van de NF-M- en 
NF-L-eiwitexpressie. Verlaging van NF-L is ook beschreven in hoofdstuk 4, waarbij ratten 
een lagere chronische dosering van 3 en 10 mg/kg oraal toegediend hebben gekregen. 
Verlaging van NF-L speelt mogelijk een belangrijke rol in de neurotoxiciteit van arseen, 
aangezien NF-H en NF-M beide een NF-L eiwit nodig hebben tot vorming van een 
heteropolymeer en het behouden van de integriteit van het cytoskelet. Verder onderzoek zoals 
in hoofdstuk 4 beschreven heeft ook laten blijken dat MAP-tau en NF-L beide sterker 
gefosforyleerd worden onder invloed van arseen in vergelijking tot de controlemonsters. 
Fosforylering van eiwitten kan leiden tot conformatieveranderingen, waarbij ze in mindere 
mate toegankelijk zijn voor interacties met andere eiwitten en dus bijdragen aan het 
destabiliseren van de zenuwintegriteit.  
En mogelijke verklaring kan zijn de activatie van het enzym calpaine, dat een calcium-
afhankelijk protease is. Verschillende studies door anderen hebben aangetoond dat arseen de 
interne calciumconcentratie in de cellen verhoogt, waardoor calpaine wordt geactiveerd, 
leidende tot NF-L afbraak en MAP-tau en NF-L hyperfosforylatie. Aan de hand van deze 
resultaten kan worden gesuggereerd dat NF-L afname een posttranslationele activiteit op eiwit 
niveau is en niet op dat van DNA/RNA. Deze conclusie wordt verder bevestigd door de 
verhoogde calpaine-expressie onder invloed van chronische aAsIII toediening, zoals is 
aangetoond in hoofdstuk 4. De afname van NF-L is een gevolg van verhoogde afbraak door 
calpaine, en niet door verlaagde NF-L expressie op RNA-niveau, zoals is aangetoond in 
hoofdstuk 5. 
In hoofdstuk 6 wordt de mogelijke verklaring beschreven van hyperfosforylering van MAP-
tau en NF-L onder invloed van arseen. Cycline-afhankelijke kinasen (Cyclin-dependent 
kinases; CDK) zijn verantwoordelijk voor de fosforylering van vele eiwitten op hun serine- en 
threonine-plaatsen. Een voorbeeld van een dergelijk kinase is CDK5 met zijn genactivator 
p35. In hoofdstuk 6 is beschreven dat onder invloed van verschillende arsenietmetabolieten, 
de p35 activator/regulator van CDK5 toeneemt in expressie. Een verhoogde expressie kan 
leiden tot verhoogde fosforylering van cytoskeleteiwitten, in het bijzonder MAP-tau en NF-L. 
Hieruit blijkt dat de verhoogde expressie alleen door driewaardig en niet door vijfwaardig 
arseen veroorzaakt wordt. Bovendien wordt p35 door calpaine gesplitst in p25 en p10. P25 is 
ook na splitsing in staat om complex te vormen met CDK5 dat leidt tot hyperactivatie en 
hyperfosforylering van cytoskeleteiwitten. 
In hoofdstuk 7 wordt een zijstap gemaakt van de hoofdlijn arseen en neurotoxiciteit, en wordt 
er gefocust op de cytotoxiteit van arseenmetabolieten in relatie tot DNA-herstelmechanisme. 
Allerlei studies hebben gesuggereerd dat arseen indirect DNA-schade veroorzaakt, door het 
DNA-herstelmechanisme te verstoren. Helaas zijn er in dit verband geen volledige studies te 
vinden, waarbij alle arseenmetabolieten getest worden. In deze oriënterende studie hebben we 
gebruik gemaakt van een drietal celtypen afkomstig van Chinese-hamsterovaria, AA8 (wild 
type), UV20 (ERCC1 deficiënt) en UV5 (ERCC2 deficiënt) in combinatie met de zes 
arseenmetabolieten in een concentratiereeks van 0 tot 100 µM. Arsenaatmetabolieten laten 
zien dat ze bij de maximale concentratie van 100 µM niet cytotoxisch zijn. 
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Arsenietmetabolieten  laten daarentegen een bijzonder beeld zien met deze drie type cellijnen. 
Bij AA8 en UV20 komen de groeiinhibitiecurven overeen voor de drie arsenietmetabolieten 
i.t.t. UV5 cellijn, waarbij een tegengesteld beeld te zien is. De gemethyleerde 
arseenmetabolieten zijn minder toxisch dan anorganisch arseen in de UV5 cellijn. Een 
mogelijke verklaring hiervoor is dat in de UV5 cellijn minder waterstofperoxide wordt 
gegeneerd door de gemethyleerde arsenietverbindingen dan door de anorganisch arseniet. Dit 
is tegengesteld aan de productie van waterstofperoxide in de beide andere cellijnen onder 
invloed van arseniet..  
Samenvattend kan gesteld worden dat ons onderzoek een bijdrage heeft geleverd tot het 
begrijpen en verklaren van het mechanisme van arseenneurotoxiciteit, oftewel; het wat en het 
hoe. Door eerst het effect op eiwitniveau in de zenuwen te bevestigen werd het wat gedeelte 
van de vraag behandeld, vervolgens werd het hoe verklaard door de afbraak en fosforylering 
van de zenuweiwitten. Hopelijk kunnen deze studies een bijdrage leveren aan het verdere 
onderzoek naar de mogelijke behandeling van arseenneurotoxiciteit. 
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